CN107243007A - 改善认知功能的方法和组合物 - Google Patents
改善认知功能的方法和组合物 Download PDFInfo
- Publication number
- CN107243007A CN107243007A CN201710440380.4A CN201710440380A CN107243007A CN 107243007 A CN107243007 A CN 107243007A CN 201710440380 A CN201710440380 A CN 201710440380A CN 107243007 A CN107243007 A CN 107243007A
- Authority
- CN
- China
- Prior art keywords
- oxo
- methyl
- hydrogen
- alkyl
- butanamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims description 81
- 230000003920 cognitive function Effects 0.000 title abstract description 33
- 238000000034 method Methods 0.000 title description 71
- 208000010877 cognitive disease Diseases 0.000 claims abstract description 72
- 229960004002 levetiracetam Drugs 0.000 claims abstract description 62
- 208000028698 Cognitive impairment Diseases 0.000 claims abstract description 48
- 208000027061 mild cognitive impairment Diseases 0.000 claims abstract description 21
- 230000007000 age related cognitive decline Effects 0.000 claims abstract description 17
- 206010027175 memory impairment Diseases 0.000 claims abstract description 8
- HPHUVLMMVZITSG-ZCFIWIBFSA-N levetiracetam Chemical compound CC[C@H](C(N)=O)N1CCCC1=O HPHUVLMMVZITSG-ZCFIWIBFSA-N 0.000 claims abstract 5
- 150000003839 salts Chemical class 0.000 claims description 72
- 239000003814 drug Substances 0.000 claims description 24
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 239000003112 inhibitor Substances 0.000 abstract description 70
- 238000011282 treatment Methods 0.000 abstract description 25
- MSYKRHVOOPPJKU-BDAKNGLRSA-N brivaracetam Chemical compound CCC[C@H]1CN([C@@H](CC)C(N)=O)C(=O)C1 MSYKRHVOOPPJKU-BDAKNGLRSA-N 0.000 abstract description 21
- 229960002161 brivaracetam Drugs 0.000 abstract description 18
- 101000584505 Homo sapiens Synaptic vesicle glycoprotein 2A Proteins 0.000 abstract description 5
- 102100030701 Synaptic vesicle glycoprotein 2A Human genes 0.000 abstract description 5
- 102000004874 Synaptophysin Human genes 0.000 abstract description 4
- 108090001076 Synaptophysin Proteins 0.000 abstract description 4
- -1 azido, carboxyl Chemical group 0.000 description 526
- 229910052739 hydrogen Inorganic materials 0.000 description 299
- 239000001257 hydrogen Substances 0.000 description 298
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 191
- 125000000217 alkyl group Chemical group 0.000 description 190
- 229910052736 halogen Inorganic materials 0.000 description 159
- 150000002367 halogens Chemical class 0.000 description 138
- 150000001875 compounds Chemical class 0.000 description 130
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 109
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 107
- 125000003118 aryl group Chemical group 0.000 description 98
- 241000700159 Rattus Species 0.000 description 88
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 74
- 125000000623 heterocyclic group Chemical group 0.000 description 69
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 68
- 125000001424 substituent group Chemical group 0.000 description 68
- 125000004093 cyano group Chemical group *C#N 0.000 description 65
- HPHUVLMMVZITSG-LURJTMIESA-N levetiracetam Chemical group CC[C@@H](C(N)=O)N1CCCC1=O HPHUVLMMVZITSG-LURJTMIESA-N 0.000 description 58
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 51
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 49
- 239000002585 base Substances 0.000 description 47
- 125000003545 alkoxy group Chemical group 0.000 description 46
- NIJJYAXOARWZEE-UHFFFAOYSA-N Valproic acid Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 43
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 43
- 125000002252 acyl group Chemical group 0.000 description 41
- 125000005843 halogen group Chemical group 0.000 description 37
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 37
- 125000004432 carbon atom Chemical group C* 0.000 description 36
- 150000002148 esters Chemical class 0.000 description 36
- 238000012549 training Methods 0.000 description 35
- 125000003342 alkenyl group Chemical group 0.000 description 34
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 32
- 125000003368 amide group Chemical group 0.000 description 31
- 125000004414 alkyl thio group Chemical group 0.000 description 29
- 125000000304 alkynyl group Chemical group 0.000 description 28
- 125000000753 cycloalkyl group Chemical group 0.000 description 26
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 26
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 25
- 239000000460 chlorine Substances 0.000 description 25
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 25
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 24
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 24
- 229910052801 chlorine Inorganic materials 0.000 description 23
- DNSISZSEWVHGLH-UHFFFAOYSA-N butanamide Chemical compound CCCC(N)=O DNSISZSEWVHGLH-UHFFFAOYSA-N 0.000 description 22
- 238000012360 testing method Methods 0.000 description 22
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 21
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 21
- 239000013543 active substance Substances 0.000 description 20
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 19
- 230000032683 aging Effects 0.000 description 19
- 229910052794 bromium Inorganic materials 0.000 description 19
- 229960000604 valproic acid Drugs 0.000 description 19
- 229910052731 fluorine Inorganic materials 0.000 description 18
- 125000002541 furyl group Chemical group 0.000 description 18
- 125000004076 pyridyl group Chemical group 0.000 description 18
- 125000006279 3-bromobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(Br)=C1[H])C([H])([H])* 0.000 description 17
- 241001465754 Metazoa Species 0.000 description 17
- 238000012347 Morris Water Maze Methods 0.000 description 17
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 17
- 230000014759 maintenance of location Effects 0.000 description 17
- 229910052760 oxygen Inorganic materials 0.000 description 17
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 17
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 17
- 230000015654 memory Effects 0.000 description 16
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 16
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 15
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 15
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 15
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 14
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 14
- 229940079593 drug Drugs 0.000 description 14
- 239000012453 solvate Substances 0.000 description 14
- 125000003837 (C1-C20) alkyl group Chemical group 0.000 description 13
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 13
- 230000006399 behavior Effects 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 125000003386 piperidinyl group Chemical group 0.000 description 13
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 13
- 229920002554 vinyl polymer Polymers 0.000 description 13
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 12
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 12
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 12
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 12
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical class O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 12
- 125000000335 thiazolyl group Chemical group 0.000 description 12
- 125000001544 thienyl group Chemical group 0.000 description 12
- 125000003396 thiol group Chemical group [H]S* 0.000 description 12
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 11
- 125000006497 3-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C(OC([H])([H])[H])=C1[H])C([H])([H])* 0.000 description 11
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 11
- 150000001412 amines Chemical class 0.000 description 11
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 11
- 239000011737 fluorine Substances 0.000 description 11
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 11
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 11
- 229910052717 sulfur Inorganic materials 0.000 description 11
- 239000003981 vehicle Substances 0.000 description 11
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 description 10
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 10
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 125000004104 aryloxy group Chemical group 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 10
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 10
- 125000002883 imidazolyl group Chemical group 0.000 description 10
- 230000001771 impaired effect Effects 0.000 description 10
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 125000000168 pyrrolyl group Chemical group 0.000 description 10
- 229940124530 sulfonamide Drugs 0.000 description 10
- 150000003456 sulfonamides Chemical class 0.000 description 10
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 10
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 9
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 241000282412 Homo Species 0.000 description 9
- 125000003282 alkyl amino group Chemical group 0.000 description 9
- 230000003542 behavioural effect Effects 0.000 description 9
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 9
- 125000002971 oxazolyl group Chemical group 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 125000003831 tetrazolyl group Chemical group 0.000 description 9
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 9
- 125000001425 triazolyl group Chemical group 0.000 description 9
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 8
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 description 8
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 8
- ZYVYEJXMYBUCMN-UHFFFAOYSA-N 1-methoxy-2-methylpropane Chemical compound COCC(C)C ZYVYEJXMYBUCMN-UHFFFAOYSA-N 0.000 description 8
- 125000004361 3,4,5-trifluorophenyl group Chemical group [H]C1=C(F)C(F)=C(F)C([H])=C1* 0.000 description 8
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 125000002837 carbocyclic group Chemical group 0.000 description 8
- 125000004122 cyclic group Chemical group 0.000 description 8
- 238000013265 extended release Methods 0.000 description 8
- 235000013305 food Nutrition 0.000 description 8
- 230000013016 learning Effects 0.000 description 8
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 8
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 8
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 8
- 125000001624 naphthyl group Chemical group 0.000 description 8
- 239000001301 oxygen Substances 0.000 description 8
- 125000004193 piperazinyl group Chemical group 0.000 description 8
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 7
- 239000004215 Carbon black (E152) Substances 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 125000004423 acyloxy group Chemical group 0.000 description 7
- 125000005110 aryl thio group Chemical group 0.000 description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 7
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 7
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 229930195733 hydrocarbon Natural products 0.000 description 7
- JYGFTBXVXVMTGB-UHFFFAOYSA-N indolin-2-one Chemical group C1=CC=C2NC(=O)CC2=C1 JYGFTBXVXVMTGB-UHFFFAOYSA-N 0.000 description 7
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 7
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 7
- 125000004430 oxygen atom Chemical group O* 0.000 description 7
- 239000001294 propane Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- DHSHMTXXPHLFOX-UHFFFAOYSA-N 1-(imidazol-1-ylmethyl)-4-propylpyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CN1C=NC=C1 DHSHMTXXPHLFOX-UHFFFAOYSA-N 0.000 description 6
- HYZJCKYKOHLVJF-SFIIULIVSA-N 1H-benzimidazole Chemical group C1=CC=C2N[11CH]=NC2=C1 HYZJCKYKOHLVJF-SFIIULIVSA-N 0.000 description 6
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 6
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 6
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 6
- HKNUWEVPOFSOKN-UHFFFAOYSA-N 4-(3-azido-2,4-difluorophenyl)-1-(imidazol-1-ylmethyl)pyrrolidin-2-one Chemical compound FC1=C(N=[N+]=[N-])C(F)=CC=C1C1CC(=O)N(CN2C=NC=C2)C1 HKNUWEVPOFSOKN-UHFFFAOYSA-N 0.000 description 6
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 6
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 6
- 208000026139 Memory disease Diseases 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 6
- 125000005135 aryl sulfinyl group Chemical group 0.000 description 6
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 6
- OBNCKNCVKJNDBV-UHFFFAOYSA-N butanoic acid ethyl ester Natural products CCCC(=O)OCC OBNCKNCVKJNDBV-UHFFFAOYSA-N 0.000 description 6
- 229910052799 carbon Inorganic materials 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 125000001309 chloro group Chemical group Cl* 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 230000006735 deficit Effects 0.000 description 6
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 125000002757 morpholinyl group Chemical group 0.000 description 6
- 125000001893 nitrooxy group Chemical group [O-][N+](=O)O* 0.000 description 6
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 6
- 125000003226 pyrazolyl group Chemical group 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 229920006395 saturated elastomer Polymers 0.000 description 6
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 125000000453 2,2,2-trichloroethyl group Chemical group [H]C([H])(*)C(Cl)(Cl)Cl 0.000 description 5
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 5
- 125000004211 3,5-difluorophenyl group Chemical group [H]C1=C(F)C([H])=C(*)C([H])=C1F 0.000 description 5
- LWOVRKKVJJZLHR-UHFFFAOYSA-N 3-[[2-oxo-4-(3,4,5-trifluorophenyl)pyrrolidin-1-yl]methyl]imidazole-4-carbonitrile Chemical compound FC1=C(F)C(F)=CC(C2CC(=O)N(CN3C(=CN=C3)C#N)C2)=C1 LWOVRKKVJJZLHR-UHFFFAOYSA-N 0.000 description 5
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 5
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 5
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 5
- 206010012289 Dementia Diseases 0.000 description 5
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Natural products CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 5
- 125000004442 acylamino group Chemical group 0.000 description 5
- 125000002947 alkylene group Chemical group 0.000 description 5
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 125000005842 heteroatom Chemical group 0.000 description 5
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000007912 intraperitoneal administration Methods 0.000 description 5
- 238000011670 long-evans rat Methods 0.000 description 5
- 125000002950 monocyclic group Chemical group 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 125000000714 pyrimidinyl group Chemical group 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 230000006886 spatial memory Effects 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 125000004434 sulfur atom Chemical group 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 5
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 4
- 125000004512 1,2,3-thiadiazol-4-yl group Chemical group S1N=NC(=C1)* 0.000 description 4
- MSTWYMAKOBGMBF-UHFFFAOYSA-N 1-(imidazol-1-ylmethyl)-4-phenylpyrrolidin-2-one Chemical compound O=C1CC(C=2C=CC=CC=2)CN1CN1C=CN=C1 MSTWYMAKOBGMBF-UHFFFAOYSA-N 0.000 description 4
- XOPQGGKKILEZAJ-UHFFFAOYSA-N 1-[[2-oxo-4-(3,4,5-trifluorophenyl)pyrrolidin-1-yl]methyl]imidazole-4-carbonitrile Chemical compound FC1=C(F)C(F)=CC(C2CC(=O)N(CN3C=C(N=C3)C#N)C2)=C1 XOPQGGKKILEZAJ-UHFFFAOYSA-N 0.000 description 4
- 125000006280 2-bromobenzyl group Chemical group [H]C1=C([H])C(Br)=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 4
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 4
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 4
- 125000006281 4-bromobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Br)C([H])([H])* 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- 208000000044 Amnesia Diseases 0.000 description 4
- 125000003860 C1-C20 alkoxy group Chemical group 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 125000005236 alkanoylamino group Chemical group 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 4
- 238000000540 analysis of variance Methods 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 125000003710 aryl alkyl group Chemical group 0.000 description 4
- 125000003725 azepanyl group Chemical group 0.000 description 4
- 125000000043 benzamido group Chemical group [H]N([*])C(=O)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 4
- 125000002619 bicyclic group Chemical group 0.000 description 4
- 239000011616 biotin Substances 0.000 description 4
- 229960002685 biotin Drugs 0.000 description 4
- 235000020958 biotin Nutrition 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 150000001721 carbon Chemical group 0.000 description 4
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 4
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 4
- 238000013270 controlled release Methods 0.000 description 4
- RFMQOHXWHFHOJF-UHFFFAOYSA-N cyano thiocyanate Chemical group N#CSC#N RFMQOHXWHFHOJF-UHFFFAOYSA-N 0.000 description 4
- 125000005879 dioxolanyl group Chemical group 0.000 description 4
- 125000004705 ethylthio group Chemical group C(C)S* 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 150000002430 hydrocarbons Chemical group 0.000 description 4
- 125000002632 imidazolidinyl group Chemical group 0.000 description 4
- 125000001041 indolyl group Chemical group 0.000 description 4
- 230000006984 memory degeneration Effects 0.000 description 4
- 208000023060 memory loss Diseases 0.000 description 4
- 238000002493 microarray Methods 0.000 description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 description 4
- 125000003431 oxalo group Chemical group 0.000 description 4
- 125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000003518 presynaptic effect Effects 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 230000009182 swimming Effects 0.000 description 4
- 230000003977 synaptic function Effects 0.000 description 4
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 4
- 125000001984 thiazolidinyl group Chemical group 0.000 description 4
- 125000005034 trifluormethylthio group Chemical group FC(S*)(F)F 0.000 description 4
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 4
- 229940102566 valproate Drugs 0.000 description 4
- IPCGCGTVOJSBDM-LURJTMIESA-N (2s)-2-(5-chloro-2-oxo-3h-indol-1-yl)propanamide Chemical compound ClC1=CC=C2N([C@@H](C)C(N)=O)C(=O)CC2=C1 IPCGCGTVOJSBDM-LURJTMIESA-N 0.000 description 3
- 125000006592 (C2-C3) alkenyl group Chemical group 0.000 description 3
- 125000006593 (C2-C3) alkynyl group Chemical group 0.000 description 3
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 3
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 3
- IXBCXRXSCZKBQM-UHFFFAOYSA-N 1-(imidazol-1-ylmethyl)-4-(3,4,5-trifluorophenyl)pyrrolidin-2-one Chemical compound FC1=C(F)C(F)=CC(C2CC(=O)N(CN3C=NC=C3)C2)=C1 IXBCXRXSCZKBQM-UHFFFAOYSA-N 0.000 description 3
- STNQVCDNZJBYBD-UHFFFAOYSA-N 1-(imidazol-1-ylmethyl)-5-methyl-3h-indol-2-one Chemical compound O=C1CC2=CC(C)=CC=C2N1CN1C=CN=C1 STNQVCDNZJBYBD-UHFFFAOYSA-N 0.000 description 3
- VKOZRIVWEOKRMT-UHFFFAOYSA-N 1-[(2-aminoimidazol-1-yl)methyl]-4-propylpyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CN1C(N)=NC=C1 VKOZRIVWEOKRMT-UHFFFAOYSA-N 0.000 description 3
- DCNPOBXGKYOEQH-UHFFFAOYSA-N 1-[(2-chloroimidazol-1-yl)methyl]-4-propylpyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CN1C(Cl)=NC=C1 DCNPOBXGKYOEQH-UHFFFAOYSA-N 0.000 description 3
- YOVXRQGGEBYKRD-UHFFFAOYSA-N 1-[(2-methylimidazol-1-yl)methyl]-4-phenylpyrrolidin-2-one Chemical compound CC1=NC=CN1CN1C(=O)CC(C=2C=CC=CC=2)C1 YOVXRQGGEBYKRD-UHFFFAOYSA-N 0.000 description 3
- TZILDGOHWVEHLW-UHFFFAOYSA-N 1-[(2-nitroimidazol-1-yl)methyl]-4-(3,4,5-trifluorophenyl)pyrrolidin-2-one Chemical compound [O-][N+](=O)C1=NC=CN1CN1C(=O)CC(C=2C=C(F)C(F)=C(F)C=2)C1 TZILDGOHWVEHLW-UHFFFAOYSA-N 0.000 description 3
- LPNDHLTVKWGIKX-UHFFFAOYSA-N 1-[(5-chloroimidazol-1-yl)methyl]-4-(3,4,5-trifluorophenyl)pyrrolidin-2-one Chemical compound FC1=C(F)C(F)=CC(C2CC(=O)N(CN3C(=CN=C3)Cl)C2)=C1 LPNDHLTVKWGIKX-UHFFFAOYSA-N 0.000 description 3
- DBFRVXYBWNTDHI-UHFFFAOYSA-N 1-[[2-oxo-4-(3,4,5-trifluorophenyl)pyrrolidin-1-yl]methyl]imidazole-2-carbonitrile Chemical compound FC1=C(F)C(F)=CC(C2CC(=O)N(CN3C(=NC=C3)C#N)C2)=C1 DBFRVXYBWNTDHI-UHFFFAOYSA-N 0.000 description 3
- 125000004343 1-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C([H])([H])[H] 0.000 description 3
- ILWHRHWCCWAGPK-UHFFFAOYSA-N 2-(5-chloro-2-oxo-3h-indol-1-yl)acetamide Chemical compound ClC1=CC=C2N(CC(=O)N)C(=O)CC2=C1 ILWHRHWCCWAGPK-UHFFFAOYSA-N 0.000 description 3
- PLHGGFRIAVVFGL-UHFFFAOYSA-N 2-(5-chloro-2-oxo-3h-indol-1-yl)butanamide Chemical compound ClC1=CC=C2N(C(CC)C(N)=O)C(=O)CC2=C1 PLHGGFRIAVVFGL-UHFFFAOYSA-N 0.000 description 3
- CQPJPPIMLJMVRK-UHFFFAOYSA-N 2-(5-methyl-2-oxo-3h-indol-1-yl)propanamide Chemical compound CC1=CC=C2N(C(C)C(N)=O)C(=O)CC2=C1 CQPJPPIMLJMVRK-UHFFFAOYSA-N 0.000 description 3
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 3
- 125000004637 2-oxopiperidinyl group Chemical class O=C1N(CCCC1)* 0.000 description 3
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 3
- WMFWFSQIINJUOM-UHFFFAOYSA-N 3-[(5-chloro-2-oxo-3h-indol-1-yl)methyl]imidazole-4-carbonitrile Chemical compound O=C1CC2=CC(Cl)=CC=C2N1CN1C=NC=C1C#N WMFWFSQIINJUOM-UHFFFAOYSA-N 0.000 description 3
- RVNGBMKIPMYIRW-UHFFFAOYSA-N 3-[[2-oxo-4-(2,3,5-trifluorophenyl)pyrrolidin-1-yl]methyl]imidazole-4-carbonitrile Chemical compound FC1=CC(F)=C(F)C(C2CC(=O)N(CN3C(=CN=C3)C#N)C2)=C1 RVNGBMKIPMYIRW-UHFFFAOYSA-N 0.000 description 3
- 125000004208 3-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C([H])C(*)=C1[H] 0.000 description 3
- GVOMOCYUXNMCEE-UHFFFAOYSA-N 4-(2,2-difluoroethenyl)-1-(imidazol-1-ylmethyl)pyrrolidin-2-one Chemical compound O=C1CC(C=C(F)F)CN1CN1C=NC=C1 GVOMOCYUXNMCEE-UHFFFAOYSA-N 0.000 description 3
- JUMOXYOJRXHGQN-UHFFFAOYSA-N 4-(3-chlorophenyl)-1-(imidazol-1-ylmethyl)pyrrolidin-2-one Chemical compound ClC1=CC=CC(C2CC(=O)N(CN3C=NC=C3)C2)=C1 JUMOXYOJRXHGQN-UHFFFAOYSA-N 0.000 description 3
- FOGVTCIVYTZIHU-UHFFFAOYSA-N 4-(3-fluorophenyl)-1-(imidazol-1-ylmethyl)pyrrolidin-2-one Chemical compound FC1=CC=CC(C2CC(=O)N(CN3C=NC=C3)C2)=C1 FOGVTCIVYTZIHU-UHFFFAOYSA-N 0.000 description 3
- VBZNNYAMASHGAS-UHFFFAOYSA-N 5-chloro-1-(imidazol-1-ylmethyl)-3h-indol-2-one Chemical compound O=C1CC2=CC(Cl)=CC=C2N1CN1C=CN=C1 VBZNNYAMASHGAS-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 3
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 3
- 240000007472 Leucaena leucocephala Species 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 229940124639 Selective inhibitor Drugs 0.000 description 3
- 125000001539 acetonyl group Chemical group [H]C([H])([H])C(=O)C([H])([H])* 0.000 description 3
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 3
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 3
- 125000001769 aryl amino group Chemical group 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 3
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 3
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 3
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 3
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 3
- 230000019771 cognition Effects 0.000 description 3
- 230000007278 cognition impairment Effects 0.000 description 3
- 230000006999 cognitive decline Effects 0.000 description 3
- 230000001149 cognitive effect Effects 0.000 description 3
- 125000000392 cycloalkenyl group Chemical group 0.000 description 3
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 3
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- YZJIOZKKQFNEOT-UHFFFAOYSA-N ethyl 2-[7-[(3-methoxyphenyl)methyl]-3-methyl-2,6-dioxopurin-8-yl]sulfanylbutanoate Chemical compound CCOC(=O)C(CC)SC1=NC=2N(C)C(=O)NC(=O)C=2N1CC1=CC=CC(OC)=C1 YZJIOZKKQFNEOT-UHFFFAOYSA-N 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 3
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 3
- 125000001188 haloalkyl group Chemical group 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 125000002346 iodo group Chemical group I* 0.000 description 3
- 125000001786 isothiazolyl group Chemical group 0.000 description 3
- 125000000842 isoxazolyl group Chemical group 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 125000006216 methylsulfinyl group Chemical group [H]C([H])([H])S(*)=O 0.000 description 3
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 3
- 125000002911 monocyclic heterocycle group Chemical group 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 125000005476 oxopyrrolidinyl group Chemical group 0.000 description 3
- 125000003884 phenylalkyl group Chemical group 0.000 description 3
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 3
- 125000003373 pyrazinyl group Chemical group 0.000 description 3
- 125000002098 pyridazinyl group Chemical group 0.000 description 3
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 3
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 3
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 3
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 125000003003 spiro group Chemical group 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 3
- 125000001113 thiadiazolyl group Chemical group 0.000 description 3
- 125000000858 thiocyanato group Chemical group *SC#N 0.000 description 3
- 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 2
- KAKMXSOLJJRKLR-AXDSSHIGSA-N (2s)-2-(2-oxo-4-thiophen-3-ylpyrrolidin-1-yl)butanamide Chemical compound C1C(=O)N([C@@H](CC)C(N)=O)CC1C1=CSC=C1 KAKMXSOLJJRKLR-AXDSSHIGSA-N 0.000 description 2
- RYZZRHSVRMVUDL-YUMQZZPRSA-N (2s)-2-[(4r)-4-ethenyl-2-oxopyrrolidin-1-yl]butanamide Chemical compound CC[C@@H](C(N)=O)N1C[C@@H](C=C)CC1=O RYZZRHSVRMVUDL-YUMQZZPRSA-N 0.000 description 2
- MSYKRHVOOPPJKU-IUCAKERBSA-N (2s)-2-[(4s)-2-oxo-4-propylpyrrolidin-1-yl]butanamide Chemical compound CCC[C@@H]1CN([C@@H](CC)C(N)=O)C(=O)C1 MSYKRHVOOPPJKU-IUCAKERBSA-N 0.000 description 2
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 description 2
- 125000006564 (C4-C8) cycloalkyl group Chemical group 0.000 description 2
- 125000006705 (C5-C7) cycloalkyl group Chemical group 0.000 description 2
- 125000000081 (C5-C8) cycloalkenyl group Chemical group 0.000 description 2
- FOBQCCYFIYFYCL-UHFFFAOYSA-N 1-(2-azido-1-imidazol-1-ylethyl)-4-propylpyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1C(CN=[N+]=[N-])N1C=NC=C1 FOBQCCYFIYFYCL-UHFFFAOYSA-N 0.000 description 2
- WQXXAPQIKCSYOZ-UHFFFAOYSA-N 1-(imidazol-1-ylmethyl)-3h-indol-2-one Chemical compound O=C1CC2=CC=CC=C2N1CN1C=CN=C1 WQXXAPQIKCSYOZ-UHFFFAOYSA-N 0.000 description 2
- YSOSTGVXSIEDJS-UHFFFAOYSA-N 1-(imidazol-1-ylmethyl)-4-(2,3,4-trifluorophenyl)pyrrolidin-2-one Chemical compound FC1=C(F)C(F)=CC=C1C1CC(=O)N(CN2C=NC=C2)C1 YSOSTGVXSIEDJS-UHFFFAOYSA-N 0.000 description 2
- NEGHKNJYVRBUIB-UHFFFAOYSA-N 1-(imidazol-1-ylmethyl)-4-(2,4,5-trifluorophenyl)pyrrolidin-2-one Chemical compound C1=C(F)C(F)=CC(F)=C1C1CC(=O)N(CN2C=NC=C2)C1 NEGHKNJYVRBUIB-UHFFFAOYSA-N 0.000 description 2
- SWMPTLGPAJVHDH-UHFFFAOYSA-N 1-(imidazol-1-ylmethyl)pyrrolidin-2-one Chemical compound O=C1CCCN1CN1C=NC=C1 SWMPTLGPAJVHDH-UHFFFAOYSA-N 0.000 description 2
- GTCYFTFNSRQATN-UHFFFAOYSA-N 1-[(2-chloroimidazol-1-yl)methyl]-4-(3,4,5-trifluorophenyl)pyrrolidin-2-one Chemical compound FC1=C(F)C(F)=CC(C2CC(=O)N(CN3C(=NC=C3)Cl)C2)=C1 GTCYFTFNSRQATN-UHFFFAOYSA-N 0.000 description 2
- LDMXDEBMEOWRSK-UHFFFAOYSA-N 1-[(2-methylimidazol-1-yl)methyl]-4-propylpyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CN1C(C)=NC=C1 LDMXDEBMEOWRSK-UHFFFAOYSA-N 0.000 description 2
- UZTJMVPOHMVXDB-UHFFFAOYSA-N 1-[(2-methylsulfanylimidazol-1-yl)methyl]-4-propylpyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CN1C(SC)=NC=C1 UZTJMVPOHMVXDB-UHFFFAOYSA-N 0.000 description 2
- QGLHAQWFXLLYML-UHFFFAOYSA-N 1-[(2-oxo-4-propylpyrrolidin-1-yl)methyl]-2-propylbenzimidazole-5-carbonitrile Chemical compound O=C1CC(CCC)CN1CN1C2=CC=C(C#N)C=C2N=C1CCC QGLHAQWFXLLYML-UHFFFAOYSA-N 0.000 description 2
- ADVHAHAQXNXOFM-UHFFFAOYSA-N 1-[(2-propan-2-ylimidazol-1-yl)methyl]-4-propylpyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CN1C(C(C)C)=NC=C1 ADVHAHAQXNXOFM-UHFFFAOYSA-N 0.000 description 2
- BNGFLFZUFMSFJR-UHFFFAOYSA-N 1-[[2-oxo-4-(2,3,4-trifluorophenyl)pyrrolidin-1-yl]methyl]imidazole-4-carbonitrile Chemical compound FC1=C(F)C(F)=CC=C1C1CC(=O)N(CN2C=C(N=C2)C#N)C1 BNGFLFZUFMSFJR-UHFFFAOYSA-N 0.000 description 2
- VQWUGPBCGAUXGV-UHFFFAOYSA-N 1-[[2-oxo-4-(2,4,5-trifluorophenyl)pyrrolidin-1-yl]methyl]imidazole-4-carbonitrile Chemical compound C1=C(F)C(F)=CC(F)=C1C1CC(=O)N(CN2C=C(N=C2)C#N)C1 VQWUGPBCGAUXGV-UHFFFAOYSA-N 0.000 description 2
- NARQRGWNGUTSFR-UHFFFAOYSA-N 1-amino-2-cyano-1-nitroguanidine Chemical compound [O-][N+](=O)N(N)C(N)=NC#N NARQRGWNGUTSFR-UHFFFAOYSA-N 0.000 description 2
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 2
- 125000006039 1-hexenyl group Chemical group 0.000 description 2
- 125000006017 1-propenyl group Chemical group 0.000 description 2
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 2
- 125000003070 2-(2-chlorophenyl)ethyl group Chemical group [H]C1=C([H])C(Cl)=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 2
- MSYKRHVOOPPJKU-UHFFFAOYSA-N 2-(2-oxo-4-propylpyrrolidin-1-yl)butanamide Chemical compound CCCC1CN(C(CC)C(N)=O)C(=O)C1 MSYKRHVOOPPJKU-UHFFFAOYSA-N 0.000 description 2
- UTTNZVOVSJFDKC-UHFFFAOYSA-N 2-(2-oxo-5-phenylpiperidin-1-yl)butanamide Chemical compound C1CC(=O)N(C(CC)C(N)=O)CC1C1=CC=CC=C1 UTTNZVOVSJFDKC-UHFFFAOYSA-N 0.000 description 2
- YGHKVKUQDBTSMG-UHFFFAOYSA-N 2-(5,7-dibromo-2-oxo-3h-indol-1-yl)acetamide Chemical compound BrC1=CC(Br)=C2N(CC(=O)N)C(=O)CC2=C1 YGHKVKUQDBTSMG-UHFFFAOYSA-N 0.000 description 2
- RMIFBHDOJWAIBA-UHFFFAOYSA-N 2-(5-bromo-2-oxo-3h-indol-1-yl)propanamide Chemical compound BrC1=CC=C2N(C(C)C(N)=O)C(=O)CC2=C1 RMIFBHDOJWAIBA-UHFFFAOYSA-N 0.000 description 2
- UFAZDCFGADNVCN-UHFFFAOYSA-N 2-(5-iodo-2-oxo-3h-indol-1-yl)acetamide Chemical compound IC1=CC=C2N(CC(=O)N)C(=O)CC2=C1 UFAZDCFGADNVCN-UHFFFAOYSA-N 0.000 description 2
- LHHUQZRUDFYTIB-UHFFFAOYSA-N 2-[2-oxo-5-(trifluoromethyl)-3h-indol-1-yl]acetamide Chemical compound FC(F)(F)C1=CC=C2N(CC(=O)N)C(=O)CC2=C1 LHHUQZRUDFYTIB-UHFFFAOYSA-N 0.000 description 2
- LKJGSQGQNWWBCZ-UHFFFAOYSA-N 2-[4-(2-fluorophenyl)-2-oxopyrrolidin-1-yl]butanamide Chemical compound C1C(=O)N(C(CC)C(N)=O)CC1C1=CC=CC=C1F LKJGSQGQNWWBCZ-UHFFFAOYSA-N 0.000 description 2
- PPDKREUWZVYRDT-UHFFFAOYSA-N 2-[4-(3,4-dichlorophenyl)-2-oxopyrrolidin-1-yl]butanamide Chemical compound C1C(=O)N(C(CC)C(N)=O)CC1C1=CC=C(Cl)C(Cl)=C1 PPDKREUWZVYRDT-UHFFFAOYSA-N 0.000 description 2
- XCKALQOJENRXGD-UHFFFAOYSA-N 2-[4-(3-chlorophenyl)-2-oxopyrrolidin-1-yl]butanamide Chemical compound C1C(=O)N(C(CC)C(N)=O)CC1C1=CC=CC(Cl)=C1 XCKALQOJENRXGD-UHFFFAOYSA-N 0.000 description 2
- DVVUVBWFUCOYRI-UHFFFAOYSA-N 2-[4-(3-methylphenyl)-2-oxopyrrolidin-1-yl]butanamide Chemical compound C1C(=O)N(C(CC)C(N)=O)CC1C1=CC=CC(C)=C1 DVVUVBWFUCOYRI-UHFFFAOYSA-N 0.000 description 2
- BPCANYYJHPHPJP-UHFFFAOYSA-N 2-[7-[(3-bromophenyl)methyl]-3-methyl-2,6-dioxopurin-8-yl]sulfanylbutanamide Chemical compound CCC(C(N)=O)SC1=NC=2N(C)C(=O)NC(=O)C=2N1CC1=CC=CC(Br)=C1 BPCANYYJHPHPJP-UHFFFAOYSA-N 0.000 description 2
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 2
- 125000004780 2-chloro-2,2-difluoroethyl group Chemical group [H]C([H])(*)C(F)(F)Cl 0.000 description 2
- 125000006040 2-hexenyl group Chemical group 0.000 description 2
- LSBDFXRDZJMBSC-UHFFFAOYSA-N 2-phenylacetamide Chemical compound NC(=O)CC1=CC=CC=C1 LSBDFXRDZJMBSC-UHFFFAOYSA-N 0.000 description 2
- NWDLCBWTNOKECX-UHFFFAOYSA-N 3-[[2-oxo-4-(2,3,4-trifluorophenyl)pyrrolidin-1-yl]methyl]imidazole-4-carbonitrile Chemical compound FC1=C(F)C(F)=CC=C1C1CC(=O)N(CN2C(=CN=C2)C#N)C1 NWDLCBWTNOKECX-UHFFFAOYSA-N 0.000 description 2
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 2
- 125000006046 3-methyl-1-pentenyl group Chemical group 0.000 description 2
- XESLNBDOUQCRDD-UHFFFAOYSA-N 4-(3,5-difluorophenyl)-1-(imidazol-1-ylmethyl)pyrrolidin-2-one Chemical compound FC1=CC(F)=CC(C2CC(=O)N(CN3C=NC=C3)C2)=C1 XESLNBDOUQCRDD-UHFFFAOYSA-N 0.000 description 2
- MPFYXCKDMXTVBZ-UHFFFAOYSA-N 4-(3-chloro-4-fluorophenyl)-1-(imidazol-1-ylmethyl)pyrrolidin-2-one Chemical compound C1=C(Cl)C(F)=CC=C1C1CC(=O)N(CN2C=NC=C2)C1 MPFYXCKDMXTVBZ-UHFFFAOYSA-N 0.000 description 2
- AFFUFXBLRDLCCR-UHFFFAOYSA-N 4-(4-chlorophenyl)-1-(imidazol-1-ylmethyl)pyrrolidin-2-one Chemical compound C1=CC(Cl)=CC=C1C1CC(=O)N(CN2C=NC=C2)C1 AFFUFXBLRDLCCR-UHFFFAOYSA-N 0.000 description 2
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 description 2
- NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 description 2
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical group NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 239000013614 RNA sample Substances 0.000 description 2
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 2
- 229910006074 SO2NH2 Inorganic materials 0.000 description 2
- 229910006069 SO3H Inorganic materials 0.000 description 2
- ANWPENAPCIFDSZ-RQJHMYQMSA-N Seletracetam Chemical compound CC[C@@H](C(N)=O)N1C[C@H](C=C(F)F)CC1=O ANWPENAPCIFDSZ-RQJHMYQMSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- OFLXLNCGODUUOT-UHFFFAOYSA-N acetohydrazide Chemical compound C\C(O)=N\N OFLXLNCGODUUOT-UHFFFAOYSA-N 0.000 description 2
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 2
- 125000003647 acryloyl group Chemical group O=C([*])C([H])=C([H])[H] 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 125000006323 alkenyl amino group Chemical group 0.000 description 2
- 125000003302 alkenyloxy group Chemical group 0.000 description 2
- 125000005136 alkenylsulfinyl group Chemical group 0.000 description 2
- 125000005137 alkenylsulfonyl group Chemical group 0.000 description 2
- 125000005108 alkenylthio group Chemical group 0.000 description 2
- 125000005037 alkyl phenyl group Chemical group 0.000 description 2
- 125000005278 alkyl sulfonyloxy group Chemical group 0.000 description 2
- 125000006319 alkynyl amino group Chemical group 0.000 description 2
- 125000004419 alkynylene group Chemical group 0.000 description 2
- 125000005133 alkynyloxy group Chemical group 0.000 description 2
- 125000005134 alkynylsulfinyl group Chemical group 0.000 description 2
- 125000005139 alkynylsulfonyl group Chemical group 0.000 description 2
- 125000005109 alkynylthio group Chemical group 0.000 description 2
- 125000005336 allyloxy group Chemical group 0.000 description 2
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 2
- 239000001961 anticonvulsive agent Substances 0.000 description 2
- 229960003965 antiepileptics Drugs 0.000 description 2
- 125000005129 aryl carbonyl group Chemical group 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 238000011952 auditory verbal learning test Methods 0.000 description 2
- 229960002756 azacitidine Drugs 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 125000004799 bromophenyl group Chemical group 0.000 description 2
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- MVHPKFQBHWGTQH-UHFFFAOYSA-N cyano(nitro)carbamic acid Chemical compound OC(=O)N(C#N)[N+]([O-])=O MVHPKFQBHWGTQH-UHFFFAOYSA-N 0.000 description 2
- NKLCHDQGUHMCGL-UHFFFAOYSA-N cyclohexylidenemethanone Chemical group O=C=C1CCCCC1 NKLCHDQGUHMCGL-UHFFFAOYSA-N 0.000 description 2
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 2
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 210000001947 dentate gyrus Anatomy 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 2
- 125000005047 dihydroimidazolyl group Chemical group N1(CNC=C1)* 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- LUPLQSFQTWFSAT-UHFFFAOYSA-N ethyl 2-(7-benzyl-1,3-dimethyl-2,6-dioxopurin-8-yl)sulfanylbutanoate Chemical compound CCOC(=O)C(CC)SC1=NC=2N(C)C(=O)N(C)C(=O)C=2N1CC1=CC=CC=C1 LUPLQSFQTWFSAT-UHFFFAOYSA-N 0.000 description 2
- WKYKNEKDZMZWFN-UHFFFAOYSA-N ethyl 2-(7-hexyl-3-methyl-2,6-dioxopurin-8-yl)sulfanylbutanoate Chemical compound CN1C(=O)NC(=O)C2=C1N=C(SC(CC)C(=O)OCC)N2CCCCCC WKYKNEKDZMZWFN-UHFFFAOYSA-N 0.000 description 2
- QRXSNXAGQFIXGC-UHFFFAOYSA-N ethyl 2-[3-methyl-7-[(5-nitrofuran-2-yl)methyl]-2,6-dioxopurin-8-yl]sulfanylbutanoate Chemical compound CCOC(=O)C(CC)SC1=NC=2N(C)C(=O)NC(=O)C=2N1CC1=CC=C([N+]([O-])=O)O1 QRXSNXAGQFIXGC-UHFFFAOYSA-N 0.000 description 2
- PPBFAKDSAHLDOQ-UHFFFAOYSA-N ethyl 2-[7-[(3,5-dimethyl-1,2-oxazol-4-yl)methyl]-3-methyl-2,6-dioxopurin-8-yl]sulfanylbutanoate Chemical compound CCOC(=O)C(CC)SC1=NC=2N(C)C(=O)NC(=O)C=2N1CC=1C(C)=NOC=1C PPBFAKDSAHLDOQ-UHFFFAOYSA-N 0.000 description 2
- OGHKZVVVZGCRHQ-UHFFFAOYSA-N ethyl 2-[7-[(3-bromophenyl)methyl]-1,3-dimethyl-2,6-dioxopurin-8-yl]sulfanylbutanoate Chemical compound CCOC(=O)C(CC)SC1=NC=2N(C)C(=O)N(C)C(=O)C=2N1CC1=CC=CC(Br)=C1 OGHKZVVVZGCRHQ-UHFFFAOYSA-N 0.000 description 2
- LJCUBNQBIPBRGD-UHFFFAOYSA-N ethyl 2-[7-[(3-bromophenyl)methyl]-1-(3-hydroxypropyl)-3-methyl-2,6-dioxopurin-8-yl]sulfanylbutanoate Chemical compound CCOC(=O)C(CC)SC1=NC=2N(C)C(=O)N(CCCO)C(=O)C=2N1CC1=CC=CC(Br)=C1 LJCUBNQBIPBRGD-UHFFFAOYSA-N 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 238000002599 functional magnetic resonance imaging Methods 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 125000000232 haloalkynyl group Chemical group 0.000 description 2
- 125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 2
- 150000002402 hexoses Chemical class 0.000 description 2
- 210000001320 hippocampus Anatomy 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 125000003037 imidazol-2-yl group Chemical group [H]N1C([*])=NC([H])=C1[H] 0.000 description 2
- 125000005945 imidazopyridyl group Chemical group 0.000 description 2
- 229940027941 immunoglobulin g Drugs 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 125000003384 isochromanyl group Chemical group C1(OCCC2=CC=CC=C12)* 0.000 description 2
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 2
- 125000005956 isoquinolyl group Chemical group 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000006996 mental state Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 125000001038 naphthoyl group Chemical group C1(=CC=CC2=CC=CC=C12)C(=O)* 0.000 description 2
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 2
- 230000003557 neuropsychological effect Effects 0.000 description 2
- 125000006501 nitrophenyl group Chemical group 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 125000000962 organic group Chemical group 0.000 description 2
- 238000007427 paired t-test Methods 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 150000002972 pentoses Chemical class 0.000 description 2
- 125000004115 pentoxy group Chemical group [*]OC([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 2
- 125000004934 phenanthridinyl group Chemical group C1(=CC=CC2=NC=C3C=CC=CC3=C12)* 0.000 description 2
- 125000004625 phenanthrolinyl group Chemical group N1=C(C=CC2=CC=C3C=CC=NC3=C12)* 0.000 description 2
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 2
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 102000016914 ras Proteins Human genes 0.000 description 2
- 108010014186 ras Proteins Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- ANWPENAPCIFDSZ-BQBZGAKWSA-N seletracetam Chemical compound CC[C@@H](C(N)=O)N1C[C@@H](C=C(F)F)CC1=O ANWPENAPCIFDSZ-BQBZGAKWSA-N 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 229940084026 sodium valproate Drugs 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 125000000547 substituted alkyl group Chemical group 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- WJXREUZUPGMAII-UHFFFAOYSA-N sulfurazidic acid Chemical compound OS(=O)(=O)N=[N+]=[N-] WJXREUZUPGMAII-UHFFFAOYSA-N 0.000 description 2
- 230000000946 synaptic effect Effects 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 230000002123 temporal effect Effects 0.000 description 2
- QIQCZROILFZKAT-UHFFFAOYSA-N tetracarbon dioxide Chemical group O=C=C=C=C=O QIQCZROILFZKAT-UHFFFAOYSA-N 0.000 description 2
- 125000004571 thiomorpholin-4-yl group Chemical group N1(CCSCC1)* 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000031836 visual learning Effects 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- KBVYGTBJAGRPOU-COBSHVIPSA-N (2r)-2-[4-(2,2-dichloroethenyl)-2-oxopyrrolidin-1-yl]butanamide Chemical compound CC[C@H](C(N)=O)N1CC(C=C(Cl)Cl)CC1=O KBVYGTBJAGRPOU-COBSHVIPSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- ZEAKEAASAZSKIE-KIYNQFGBSA-N (2s)-2-(2-oxo-4-phenylpyrrolidin-1-yl)butanamide Chemical compound C1C(=O)N([C@@H](CC)C(N)=O)CC1C1=CC=CC=C1 ZEAKEAASAZSKIE-KIYNQFGBSA-N 0.000 description 1
- ZVUSGGRVXFWBMI-AXDSSHIGSA-N (2s)-2-(2-oxo-4-pyrrol-1-ylpyrrolidin-1-yl)butanamide Chemical compound C1C(=O)N([C@@H](CC)C(N)=O)CC1N1C=CC=C1 ZVUSGGRVXFWBMI-AXDSSHIGSA-N 0.000 description 1
- XJWASPPPXXALSD-GKAPJAKFSA-N (2s)-2-(2-oxo-4-thiophen-2-ylpyrrolidin-1-yl)butanamide Chemical compound C1C(=O)N([C@@H](CC)C(N)=O)CC1C1=CC=CS1 XJWASPPPXXALSD-GKAPJAKFSA-N 0.000 description 1
- BACGRHSREICCAJ-QMMMGPOBSA-N (2s)-2-(2-oxoazepan-1-yl)butanamide Chemical class CC[C@@H](C(N)=O)N1CCCCCC1=O BACGRHSREICCAJ-QMMMGPOBSA-N 0.000 description 1
- FBIVVFBRBKQARX-ZETCQYMHSA-N (2s)-2-(2-oxopiperidin-1-yl)butanamide Chemical compound CC[C@@H](C(N)=O)N1CCCCC1=O FBIVVFBRBKQARX-ZETCQYMHSA-N 0.000 description 1
- DGHFMPOTXCGXRM-HKGPVOKGSA-N (2s)-2-(2-oxopyrrolidin-1-yl)butanamide Chemical compound CC[C@@H](C(N)=O)N1CCCC1=O.CC[C@@H](C(N)=O)N1CCCC1=O DGHFMPOTXCGXRM-HKGPVOKGSA-N 0.000 description 1
- XHWKNGLLYBNSBG-MQWKRIRWSA-N (2s)-2-(4-ethyl-2-oxopyrrolidin-1-yl)butanamide Chemical compound CC[C@@H](C(N)=O)N1CC(CC)CC1=O XHWKNGLLYBNSBG-MQWKRIRWSA-N 0.000 description 1
- RNJBGSHJUDJSAL-QHGLUPRGSA-N (2s)-2-(4-methyl-2-oxo-4-propylpyrrolidin-1-yl)butanamide Chemical compound CCCC1(C)CN([C@@H](CC)C(N)=O)C(=O)C1 RNJBGSHJUDJSAL-QHGLUPRGSA-N 0.000 description 1
- ZPKHWWVHQIJEIN-BQBZGAKWSA-N (2s)-2-[(4r)-4-(2,2-dibromoethenyl)-2-oxopyrrolidin-1-yl]butanamide Chemical compound CC[C@@H](C(N)=O)N1C[C@@H](C=C(Br)Br)CC1=O ZPKHWWVHQIJEIN-BQBZGAKWSA-N 0.000 description 1
- YEVVLMVRPFGRTB-BQBZGAKWSA-N (2s)-2-[(4r)-4-(azidomethyl)-2-oxopyrrolidin-1-yl]butanamide Chemical compound CC[C@@H](C(N)=O)N1C[C@H](CN=[N+]=[N-])CC1=O YEVVLMVRPFGRTB-BQBZGAKWSA-N 0.000 description 1
- LYHWYWWLWAVRMW-YUMQZZPRSA-N (2s)-2-[(4r)-4-(iodomethyl)-2-oxopyrrolidin-1-yl]-n-methylbutanamide Chemical compound CNC(=O)[C@H](CC)N1C[C@H](CI)CC1=O LYHWYWWLWAVRMW-YUMQZZPRSA-N 0.000 description 1
- MUAFOMJSWIWBTJ-BQBZGAKWSA-N (2s)-2-[(4r)-4-(iodomethyl)-2-oxopyrrolidin-1-yl]butanamide Chemical compound CC[C@@H](C(N)=O)N1C[C@H](CI)CC1=O MUAFOMJSWIWBTJ-BQBZGAKWSA-N 0.000 description 1
- XZTTUEMSQNMNAC-YUMQZZPRSA-N (2s)-2-[(4r)-4-(iodomethyl)-2-oxopyrrolidin-1-yl]pentanamide Chemical compound CCC[C@@H](C(N)=O)N1C[C@H](CI)CC1=O XZTTUEMSQNMNAC-YUMQZZPRSA-N 0.000 description 1
- MJDBKFOLHGJPHI-WDSKDSINSA-N (2s)-2-[(4r)-4-(iodomethyl)-2-oxopyrrolidin-1-yl]propanamide Chemical compound NC(=O)[C@H](C)N1C[C@H](CI)CC1=O MJDBKFOLHGJPHI-WDSKDSINSA-N 0.000 description 1
- ZPKHWWVHQIJEIN-RQJHMYQMSA-N (2s)-2-[(4s)-4-(2,2-dibromoethenyl)-2-oxopyrrolidin-1-yl]butanamide Chemical compound CC[C@@H](C(N)=O)N1C[C@H](C=C(Br)Br)CC1=O ZPKHWWVHQIJEIN-RQJHMYQMSA-N 0.000 description 1
- RYZZRHSVRMVUDL-SFYZADRCSA-N (2s)-2-[(4s)-4-ethenyl-2-oxopyrrolidin-1-yl]butanamide Chemical compound CC[C@@H](C(N)=O)N1C[C@H](C=C)CC1=O RYZZRHSVRMVUDL-SFYZADRCSA-N 0.000 description 1
- VMXHHIUMVBUSJA-GKAPJAKFSA-N (2s)-2-[2-oxo-4-(2-oxopropyl)pyrrolidin-1-yl]butanamide Chemical compound CC[C@@H](C(N)=O)N1CC(CC(C)=O)CC1=O VMXHHIUMVBUSJA-GKAPJAKFSA-N 0.000 description 1
- IKMSRYNPTUDYBB-KZUDCZAMSA-N (2s)-2-[2-oxo-4-(2-phenylethyl)pyrrolidin-1-yl]butanamide Chemical compound C1C(=O)N([C@@H](CC)C(N)=O)CC1CCC1=CC=CC=C1 IKMSRYNPTUDYBB-KZUDCZAMSA-N 0.000 description 1
- LJBKVYFUXPAUJV-MQWKRIRWSA-N (2s)-2-[2-oxo-4-(3,3,3-trifluoropropyl)pyrrolidin-1-yl]butanamide Chemical compound CC[C@@H](C(N)=O)N1CC(CCC(F)(F)F)CC1=O LJBKVYFUXPAUJV-MQWKRIRWSA-N 0.000 description 1
- IUGMWDRZYAPZDK-LOACHALJSA-N (2s)-2-[2-oxo-4-(3-phenylpropyl)pyrrolidin-1-yl]butanamide Chemical compound C1C(=O)N([C@@H](CC)C(N)=O)CC1CCCC1=CC=CC=C1 IUGMWDRZYAPZDK-LOACHALJSA-N 0.000 description 1
- QTCQXVMHJZYYCE-ZVAWYAOSSA-N (2s)-2-[2-oxo-4-(4-phenylphenyl)pyrrolidin-1-yl]butanamide Chemical compound C1C(=O)N([C@@H](CC)C(N)=O)CC1C1=CC=C(C=2C=CC=CC=2)C=C1 QTCQXVMHJZYYCE-ZVAWYAOSSA-N 0.000 description 1
- HXSYUKBJWISQLD-MQWKRIRWSA-N (2s)-2-[2-oxo-4-(tetrazol-1-ylmethyl)pyrrolidin-1-yl]butanamide Chemical compound C1C(=O)N([C@@H](CC)C(N)=O)CC1CN1N=NN=C1 HXSYUKBJWISQLD-MQWKRIRWSA-N 0.000 description 1
- OAWBNDBXEGMTMK-AXDSSHIGSA-N (2s)-2-[4-(2,2-dimethylpropyl)-2-oxopyrrolidin-1-yl]butanamide Chemical compound CC[C@@H](C(N)=O)N1CC(CC(C)(C)C)CC1=O OAWBNDBXEGMTMK-AXDSSHIGSA-N 0.000 description 1
- GYMMJGNIZFXYQD-MQWKRIRWSA-N (2s)-2-[4-(2-bromoethynyl)-2-oxopyrrolidin-1-yl]butanamide Chemical compound CC[C@@H](C(N)=O)N1CC(C#CBr)CC1=O GYMMJGNIZFXYQD-MQWKRIRWSA-N 0.000 description 1
- QJISPLGXDRVSGR-GKAPJAKFSA-N (2s)-2-[4-(2-bromopyrrol-1-yl)-2-oxopyrrolidin-1-yl]butanamide Chemical compound C1C(=O)N([C@@H](CC)C(N)=O)CC1N1C(Br)=CC=C1 QJISPLGXDRVSGR-GKAPJAKFSA-N 0.000 description 1
- UMWCSODNRCPYON-HACHORDNSA-N (2s)-2-[4-(2-iodopropyl)-2-oxopyrrolidin-1-yl]butanamide Chemical compound CC[C@@H](C(N)=O)N1CC(CC(C)I)CC1=O UMWCSODNRCPYON-HACHORDNSA-N 0.000 description 1
- VXRYGNQOLKBSFO-KFJBMODSSA-N (2s)-2-[4-(2-methoxyphenyl)-2-oxopyrrolidin-1-yl]butanamide Chemical compound C1C(=O)N([C@@H](CC)C(N)=O)CC1C1=CC=CC=C1OC VXRYGNQOLKBSFO-KFJBMODSSA-N 0.000 description 1
- MGULPUMVXJDSMK-ACGXKRRESA-N (2s)-2-[4-(3,5-dibromophenyl)-2-oxopyrrolidin-1-yl]butanamide Chemical compound C1C(=O)N([C@@H](CC)C(N)=O)CC1C1=CC(Br)=CC(Br)=C1 MGULPUMVXJDSMK-ACGXKRRESA-N 0.000 description 1
- HJTWBNCCSFVTLK-KFJBMODSSA-N (2s)-2-[4-(3-azidophenyl)-2-oxopyrrolidin-1-yl]butanamide Chemical compound C1C(=O)N([C@@H](CC)C(N)=O)CC1C1=CC=CC(N=[N+]=[N-])=C1 HJTWBNCCSFVTLK-KFJBMODSSA-N 0.000 description 1
- ZAUOGJBDPVSTPS-KFJBMODSSA-N (2s)-2-[4-(3-bromophenyl)-2-oxopyrrolidin-1-yl]butanamide Chemical compound C1C(=O)N([C@@H](CC)C(N)=O)CC1C1=CC=CC(Br)=C1 ZAUOGJBDPVSTPS-KFJBMODSSA-N 0.000 description 1
- AASSBJLQVGJIET-YUZLPWPTSA-N (2s)-2-[4-(3-methoxyphenyl)-2-oxopyrrolidin-1-yl]butanamide Chemical compound C1C(=O)N([C@@H](CC)C(N)=O)CC1C1=CC=CC(OC)=C1 AASSBJLQVGJIET-YUZLPWPTSA-N 0.000 description 1
- XHGBFFLVARRQMJ-KFJBMODSSA-N (2s)-2-[4-(4-azidophenyl)-2-oxopyrrolidin-1-yl]butanamide Chemical compound C1C(=O)N([C@@H](CC)C(N)=O)CC1C1=CC=C(N=[N+]=[N-])C=C1 XHGBFFLVARRQMJ-KFJBMODSSA-N 0.000 description 1
- JYEMBFRGGJXHBH-MLWJPKLSSA-N (2s)-2-[4-(bromomethyl)-2-oxopyrrolidin-1-yl]butanamide Chemical compound CC[C@@H](C(N)=O)N1CC(CBr)CC1=O JYEMBFRGGJXHBH-MLWJPKLSSA-N 0.000 description 1
- PEJPXWBXHQKKNX-MLWJPKLSSA-N (2s)-2-[4-(chloromethyl)-2-oxopyrrolidin-1-yl]butanamide Chemical compound CC[C@@H](C(N)=O)N1CC(CCl)CC1=O PEJPXWBXHQKKNX-MLWJPKLSSA-N 0.000 description 1
- IHYNOEHNHISISC-AXDSSHIGSA-N (2s)-2-[4-(cyclopropylmethyl)-2-oxopyrrolidin-1-yl]butanamide Chemical compound C1C(=O)N([C@@H](CC)C(N)=O)CC1CC1CC1 IHYNOEHNHISISC-AXDSSHIGSA-N 0.000 description 1
- PAMQVXOBQOEDRC-MQWKRIRWSA-N (2s)-2-[4-(iodomethyl)-2-oxopiperidin-1-yl]butanamide Chemical compound CC[C@@H](C(N)=O)N1CCC(CI)CC1=O PAMQVXOBQOEDRC-MQWKRIRWSA-N 0.000 description 1
- MUAFOMJSWIWBTJ-MLWJPKLSSA-N (2s)-2-[4-(iodomethyl)-2-oxopyrrolidin-1-yl]butanamide Chemical compound CC[C@@H](C(N)=O)N1CC(CI)CC1=O MUAFOMJSWIWBTJ-MLWJPKLSSA-N 0.000 description 1
- XOFFNXIJSCUXQG-MQWKRIRWSA-N (2s)-2-[5-(azidomethyl)-2-oxopiperidin-1-yl]butanamide Chemical compound CC[C@@H](C(N)=O)N1CC(CN=[N+]=[N-])CCC1=O XOFFNXIJSCUXQG-MQWKRIRWSA-N 0.000 description 1
- UDKQJJFZWIUVFH-MQWKRIRWSA-N (2s)-2-[5-(iodomethyl)-2-oxopiperidin-1-yl]butanamide Chemical compound CC[C@@H](C(N)=O)N1CC(CI)CCC1=O UDKQJJFZWIUVFH-MQWKRIRWSA-N 0.000 description 1
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 description 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 1
- 125000006710 (C2-C12) alkenyl group Chemical group 0.000 description 1
- 125000006730 (C2-C5) alkynyl group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- LGXVIGDEPROXKC-UHFFFAOYSA-N 1,1-dichloroethene Chemical compound ClC(Cl)=C LGXVIGDEPROXKC-UHFFFAOYSA-N 0.000 description 1
- NLSXMAXNRDFBKV-UHFFFAOYSA-N 1-(1-imidazol-1-ylcyclopropyl)pyrrolidin-2-one Chemical compound O=C1CCCN1C1(N2C=NC=C2)CC1 NLSXMAXNRDFBKV-UHFFFAOYSA-N 0.000 description 1
- YBKBOKXXZSREFD-UHFFFAOYSA-N 1-(benzimidazol-1-ylmethyl)-4-propylpyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CN1C2=CC=CC=C2N=C1 YBKBOKXXZSREFD-UHFFFAOYSA-N 0.000 description 1
- MMPUPJTXJGUJCN-UHFFFAOYSA-N 1-(imidazol-1-ylmethyl)-4-(2,3,5-trifluorophenyl)pyrrolidin-2-one Chemical compound FC1=CC(F)=C(F)C(C2CC(=O)N(CN3C=NC=C3)C2)=C1 MMPUPJTXJGUJCN-UHFFFAOYSA-N 0.000 description 1
- LILRFAHFFHHJTB-UHFFFAOYSA-N 1-[(2,4-dichloroimidazol-1-yl)methyl]-4-(3,4,5-trifluorophenyl)pyrrolidin-2-one Chemical compound FC1=C(F)C(F)=CC(C2CC(=O)N(CN3C(=NC(Cl)=C3)Cl)C2)=C1 LILRFAHFFHHJTB-UHFFFAOYSA-N 0.000 description 1
- DMWXHPXTQSABEU-UHFFFAOYSA-N 1-[(2,5-dimethylimidazol-1-yl)methyl]-4-propylpyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CN1C(C)=NC=C1C DMWXHPXTQSABEU-UHFFFAOYSA-N 0.000 description 1
- DXFJCDZVYSJJJW-UHFFFAOYSA-N 1-[(2-aminobenzimidazol-1-yl)methyl]-4-propylpyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CN1C2=CC=CC=C2N=C1N DXFJCDZVYSJJJW-UHFFFAOYSA-N 0.000 description 1
- HZIUYKJGHVOBOT-UHFFFAOYSA-N 1-[(2-bromo-4,5-dichloroimidazol-1-yl)methyl]-4-propylpyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CN1C(Cl)=C(Cl)N=C1Br HZIUYKJGHVOBOT-UHFFFAOYSA-N 0.000 description 1
- WFNPPGOEDWYTLY-UHFFFAOYSA-N 1-[(2-cyclopropyl-5-fluorobenzimidazol-1-yl)methyl]-4-propylpyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CN1C2=CC=C(F)C=C2N=C1C1CC1 WFNPPGOEDWYTLY-UHFFFAOYSA-N 0.000 description 1
- UKKWMLOZDLBREX-UHFFFAOYSA-N 1-[(2-cyclopropyl-6-methoxybenzimidazol-1-yl)methyl]-4-propylpyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CN1C2=CC(OC)=CC=C2N=C1C1CC1 UKKWMLOZDLBREX-UHFFFAOYSA-N 0.000 description 1
- BCTSBRXYGVKFIQ-UHFFFAOYSA-N 1-[(2-ethyl-5-methylimidazol-1-yl)methyl]-4-propylpyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CN1C(CC)=NC=C1C BCTSBRXYGVKFIQ-UHFFFAOYSA-N 0.000 description 1
- XNAQRBOXVOAHBN-UHFFFAOYSA-N 1-[(2-ethylimidazol-1-yl)methyl]-4-propylpyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CN1C(CC)=NC=C1 XNAQRBOXVOAHBN-UHFFFAOYSA-N 0.000 description 1
- KMJYGLVZFWVDEX-UHFFFAOYSA-N 1-[(2-methylbenzimidazol-1-yl)methyl]-4-propylpyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CN1C2=CC=CC=C2N=C1C KMJYGLVZFWVDEX-UHFFFAOYSA-N 0.000 description 1
- UEHLNJNATLEAND-UHFFFAOYSA-N 1-[(2-methylsulfanylbenzimidazol-1-yl)methyl]-4-propylpyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CN1C2=CC=CC=C2N=C1SC UEHLNJNATLEAND-UHFFFAOYSA-N 0.000 description 1
- WSNFJRAAUWGARO-UHFFFAOYSA-N 1-[(2-methylsulfinylimidazol-1-yl)methyl]-4-propylpyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CN1C(S(C)=O)=NC=C1 WSNFJRAAUWGARO-UHFFFAOYSA-N 0.000 description 1
- QRILSCCZFKIUCY-UHFFFAOYSA-N 1-[(2-oxo-4-propylpyrrolidin-1-yl)methyl]-2-(1h-pyrazol-5-yl)benzimidazole-5-carbonitrile Chemical compound O=C1CC(CCC)CN1CN1C2=CC=C(C#N)C=C2N=C1C1=NNC=C1 QRILSCCZFKIUCY-UHFFFAOYSA-N 0.000 description 1
- KYAPYLNXHWPLFH-UHFFFAOYSA-N 1-[(2-oxo-4-propylpyrrolidin-1-yl)methyl]imidazole-2-carboxamide Chemical compound O=C1CC(CCC)CN1CN1C(C(N)=O)=NC=C1 KYAPYLNXHWPLFH-UHFFFAOYSA-N 0.000 description 1
- UBSFWHNQTAFWBM-UHFFFAOYSA-N 1-[(2-phenylimidazol-1-yl)methyl]-4-propylpyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CN1C(C=2C=CC=CC=2)=NC=C1 UBSFWHNQTAFWBM-UHFFFAOYSA-N 0.000 description 1
- SPKIWIWRIXDINF-UHFFFAOYSA-N 1-[(2-propan-2-ylbenzimidazol-1-yl)methyl]-4-propylpyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CN1C2=CC=CC=C2N=C1C(C)C SPKIWIWRIXDINF-UHFFFAOYSA-N 0.000 description 1
- JQNJBZAGGUCOSU-UHFFFAOYSA-N 1-[(4-chloroimidazol-1-yl)methyl]-4-(3,4,5-trifluorophenyl)pyrrolidin-2-one Chemical compound FC1=C(F)C(F)=CC(C2CC(=O)N(CN3C=C(Cl)N=C3)C2)=C1 JQNJBZAGGUCOSU-UHFFFAOYSA-N 0.000 description 1
- GMPLEBLTRDQYQU-UHFFFAOYSA-N 1-[(5,6-dimethylbenzimidazol-1-yl)methyl]-4-propylpyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CN1C2=CC(C)=C(C)C=C2N=C1 GMPLEBLTRDQYQU-UHFFFAOYSA-N 0.000 description 1
- LYRJZOWYSWXWAV-UHFFFAOYSA-N 1-[(5-fluoro-2-propan-2-ylbenzimidazol-1-yl)methyl]-4-propylpyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CN1C2=CC=C(F)C=C2N=C1C(C)C LYRJZOWYSWXWAV-UHFFFAOYSA-N 0.000 description 1
- MWSZIXPMBFLEIE-UHFFFAOYSA-N 1-[(5-fluoro-2-propylbenzimidazol-1-yl)methyl]-4-propylpyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CN1C2=CC=C(F)C=C2N=C1CCC MWSZIXPMBFLEIE-UHFFFAOYSA-N 0.000 description 1
- FIUGWBYGVGENPO-UHFFFAOYSA-N 1-[(5-methoxybenzimidazol-1-yl)methyl]-4-propylpyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CN1C2=CC=C(OC)C=C2N=C1 FIUGWBYGVGENPO-UHFFFAOYSA-N 0.000 description 1
- MMOGPHOGLIXALW-UHFFFAOYSA-N 1-[(5-methylbenzimidazol-1-yl)methyl]-4-propylpyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CN1C2=CC=C(C)C=C2N=C1 MMOGPHOGLIXALW-UHFFFAOYSA-N 0.000 description 1
- RYELIZJHVRUBPL-UHFFFAOYSA-N 1-[(5-methylimidazol-1-yl)methyl]-4-propylpyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CN1C(C)=CN=C1 RYELIZJHVRUBPL-UHFFFAOYSA-N 0.000 description 1
- XZAPIBFOEWKGEW-UHFFFAOYSA-N 1-[(5-phenylimidazol-1-yl)methyl]-4-propylpyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CN1C(C=2C=CC=CC=2)=CN=C1 XZAPIBFOEWKGEW-UHFFFAOYSA-N 0.000 description 1
- POYAFCUMHBKUJT-UHFFFAOYSA-N 1-[(6-chlorobenzimidazol-1-yl)methyl]-4-propylpyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CN1C2=CC(Cl)=CC=C2N=C1 POYAFCUMHBKUJT-UHFFFAOYSA-N 0.000 description 1
- ODGJZBDHLRKMJH-UHFFFAOYSA-N 1-[(6-methoxy-2-pentan-3-ylbenzimidazol-1-yl)methyl]-4-propylpyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CN1C2=CC(OC)=CC=C2N=C1C(CC)CC ODGJZBDHLRKMJH-UHFFFAOYSA-N 0.000 description 1
- XXAIPQNCTCVZLJ-UHFFFAOYSA-N 1-[(6-methoxy-2-propan-2-ylbenzimidazol-1-yl)methyl]-4-propylpyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CN1C2=CC(OC)=CC=C2N=C1C(C)C XXAIPQNCTCVZLJ-UHFFFAOYSA-N 0.000 description 1
- XYQOCEDJKXMZIH-UHFFFAOYSA-N 1-[(6-methoxy-2-propylbenzimidazol-1-yl)methyl]-4-propylpyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CN1C2=CC(OC)=CC=C2N=C1CCC XYQOCEDJKXMZIH-UHFFFAOYSA-N 0.000 description 1
- BWUYHRBEWKNROO-UHFFFAOYSA-N 1-[1-(2-methylsulfonylimidazol-1-yl)butan-2-yl]pyrrolidin-2-one Chemical compound C1CCC(=O)N1C(CC)CN1C=CN=C1S(C)(=O)=O BWUYHRBEWKNROO-UHFFFAOYSA-N 0.000 description 1
- PLOISAVDJJVIDJ-UHFFFAOYSA-N 1-[2-(5-chloro-2-oxo-3h-indol-1-yl)acetyl]-2,3,4a,5,6,7,8,8a-octahydroquinolin-4-one Chemical compound C1CC(=O)C2CCCCC2N1C(=O)CN1C2=CC=C(Cl)C=C2CC1=O PLOISAVDJJVIDJ-UHFFFAOYSA-N 0.000 description 1
- QINPXWIQALJJMO-UHFFFAOYSA-N 1-[[2-(1H-imidazol-2-yl)-5-(trifluoromethyl)benzimidazol-1-yl]methyl]-4-propylpyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CN1C2=CC=C(C(F)(F)F)C=C2N=C1C1=NC=CN1 QINPXWIQALJJMO-UHFFFAOYSA-N 0.000 description 1
- BNKDDYUJRZNHNO-UHFFFAOYSA-N 1-[[2-(2-methylsulfanylethyl)-5-(trifluoromethyl)benzimidazol-1-yl]methyl]-4-propylpyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CN1C2=CC=C(C(F)(F)F)C=C2N=C1CCSC BNKDDYUJRZNHNO-UHFFFAOYSA-N 0.000 description 1
- LWNMPCACKLXIGW-UHFFFAOYSA-N 1-[[2-(chloromethyl)benzimidazol-1-yl]methyl]-4-propylpyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CN1C2=CC=CC=C2N=C1CCl LWNMPCACKLXIGW-UHFFFAOYSA-N 0.000 description 1
- LBTYIARANZCFLB-UHFFFAOYSA-N 1-[[2-(furan-2-yl)-5-(trifluoromethyl)benzimidazol-1-yl]methyl]-4-propylpyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CN1C2=CC=C(C(F)(F)F)C=C2N=C1C1=CC=CO1 LBTYIARANZCFLB-UHFFFAOYSA-N 0.000 description 1
- YTSOXQXOEYSMDY-UHFFFAOYSA-N 1-[[2-(furan-3-yl)-5-(trifluoromethyl)benzimidazol-1-yl]methyl]-4-propylpyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CN1C2=CC=C(C(F)(F)F)C=C2N=C1C1=COC=C1 YTSOXQXOEYSMDY-UHFFFAOYSA-N 0.000 description 1
- RMMCPJJDTQULOI-UHFFFAOYSA-N 1-[[2-(furan-3-yl)-6-methoxybenzimidazol-1-yl]methyl]-4-propylpyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CN1C2=CC(OC)=CC=C2N=C1C1=COC=C1 RMMCPJJDTQULOI-UHFFFAOYSA-N 0.000 description 1
- XXKQXJBAACVLAJ-UHFFFAOYSA-N 1-[[2-(hydroxymethyl)imidazol-1-yl]methyl]-4-propylpyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CN1C(CO)=NC=C1 XXKQXJBAACVLAJ-UHFFFAOYSA-N 0.000 description 1
- HQVGICWOGFCPOQ-UHFFFAOYSA-N 1-[[2-ethyl-5-(trifluoromethyl)benzimidazol-1-yl]methyl]-4-propylpyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CN1C2=CC=C(C(F)(F)F)C=C2N=C1CC HQVGICWOGFCPOQ-UHFFFAOYSA-N 0.000 description 1
- PTFZZCVHKGBHJB-UHFFFAOYSA-N 1-[[2-oxo-4-(2,3,5-trifluorophenyl)pyrrolidin-1-yl]methyl]imidazole-4-carbonitrile Chemical compound FC1=CC(F)=C(F)C(C2CC(=O)N(CN3C=C(N=C3)C#N)C2)=C1 PTFZZCVHKGBHJB-UHFFFAOYSA-N 0.000 description 1
- WDFZRXNIRFYZLW-UHFFFAOYSA-N 1-[[6-methoxy-2-(1-methylpyrrol-2-yl)benzimidazol-1-yl]methyl]-4-propylpyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CN1C2=CC(OC)=CC=C2N=C1C1=CC=CN1C WDFZRXNIRFYZLW-UHFFFAOYSA-N 0.000 description 1
- PXSLMJKKTSVLAS-UHFFFAOYSA-N 1-[[6-methyl-2-(1H-pyrrol-2-yl)benzimidazol-1-yl]methyl]-4-propylpyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CN1C2=CC(C)=CC=C2N=C1C1=CC=CN1 PXSLMJKKTSVLAS-UHFFFAOYSA-N 0.000 description 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
- LIKMAJRDDDTEIG-UHFFFAOYSA-N 1-hexene Chemical group CCCCC=C LIKMAJRDDDTEIG-UHFFFAOYSA-N 0.000 description 1
- 125000006055 1-methyl-4-pentenyl group Chemical group 0.000 description 1
- RPABADYMEMUBEC-UHFFFAOYSA-N 1-oxaspiro[4.5]decan-8-one Chemical compound C1CC(=O)CCC11OCCC1 RPABADYMEMUBEC-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- WGBKFDDNOXHFGE-UHFFFAOYSA-N 2-(2-oxo-4-pentylpyrrolidin-1-yl)butanamide Chemical compound CCCCCC1CN(C(CC)C(N)=O)C(=O)C1 WGBKFDDNOXHFGE-UHFFFAOYSA-N 0.000 description 1
- NFSZFGROITVARK-UHFFFAOYSA-N 2-(2-oxo-4-phenylazepan-1-yl)butanamide Chemical compound C1C(=O)N(C(CC)C(N)=O)CCCC1C1=CC=CC=C1 NFSZFGROITVARK-UHFFFAOYSA-N 0.000 description 1
- OOYXPFWOTPALAY-UHFFFAOYSA-N 2-(2-oxo-4-phenylpiperidin-1-yl)butanamide Chemical compound C1C(=O)N(C(CC)C(N)=O)CCC1C1=CC=CC=C1 OOYXPFWOTPALAY-UHFFFAOYSA-N 0.000 description 1
- OVFBPHYYEMZVEQ-UHFFFAOYSA-N 2-(2-oxo-4-prop-1-ynylazepan-1-yl)butanamide Chemical compound CCC(C(N)=O)N1CCCC(C#CC)CC1=O OVFBPHYYEMZVEQ-UHFFFAOYSA-N 0.000 description 1
- KTJVFWOBNSUBBI-UHFFFAOYSA-N 2-(2-oxo-4-prop-1-ynylpiperidin-1-yl)butanamide Chemical compound CCC(C(N)=O)N1CCC(C#CC)CC1=O KTJVFWOBNSUBBI-UHFFFAOYSA-N 0.000 description 1
- ROMNFXNQODIBHN-UHFFFAOYSA-N 2-(2-oxo-4-propylazepan-1-yl)butanamide Chemical compound CCCC1CCCN(C(CC)C(N)=O)C(=O)C1 ROMNFXNQODIBHN-UHFFFAOYSA-N 0.000 description 1
- BAIMGBARCXSMCE-UHFFFAOYSA-N 2-(2-oxo-4-propylpiperidin-1-yl)butanamide Chemical compound CCCC1CCN(C(CC)C(N)=O)C(=O)C1 BAIMGBARCXSMCE-UHFFFAOYSA-N 0.000 description 1
- DFBAGGAGICLBQZ-UHFFFAOYSA-N 2-(2-oxo-4-propylpyrrolidin-1-yl)-3-(1,3-thiazol-4-yl)propanamide Chemical compound O=C1CC(CCC)CN1C(C(N)=O)CC1=CSC=N1 DFBAGGAGICLBQZ-UHFFFAOYSA-N 0.000 description 1
- HAZDGRIPRJYBOR-UHFFFAOYSA-N 2-(2-oxo-4-propylpyrrolidin-1-yl)pentanamide Chemical compound CCCC(C(N)=O)N1CC(CCC)CC1=O HAZDGRIPRJYBOR-UHFFFAOYSA-N 0.000 description 1
- SCGUKHNLKPVJGD-UHFFFAOYSA-N 2-(2-oxo-4-propylpyrrolidin-1-yl)propanamide Chemical compound CCCC1CN(C(C)C(N)=O)C(=O)C1 SCGUKHNLKPVJGD-UHFFFAOYSA-N 0.000 description 1
- WCFSNOUAIPGJNH-UHFFFAOYSA-N 2-(2-oxo-4-pyridin-3-ylpyrrolidin-1-yl)butanamide Chemical compound C1C(=O)N(C(CC)C(N)=O)CC1C1=CC=CN=C1 WCFSNOUAIPGJNH-UHFFFAOYSA-N 0.000 description 1
- LWJQTIUSGQVIEA-UHFFFAOYSA-N 2-(2-oxo-4-thiophen-2-ylazepan-1-yl)butanamide Chemical compound C1C(=O)N(C(CC)C(N)=O)CCCC1C1=CC=CS1 LWJQTIUSGQVIEA-UHFFFAOYSA-N 0.000 description 1
- XVRHTMKNQDAFFP-UHFFFAOYSA-N 2-(2-oxo-4-thiophen-2-ylpiperidin-1-yl)butanamide Chemical compound C1C(=O)N(C(CC)C(N)=O)CCC1C1=CC=CS1 XVRHTMKNQDAFFP-UHFFFAOYSA-N 0.000 description 1
- UOWZKAMMCADMCA-UHFFFAOYSA-N 2-(2-oxo-4-thiophen-3-ylazepan-1-yl)butanamide Chemical compound C1C(=O)N(C(CC)C(N)=O)CCCC1C1=CSC=C1 UOWZKAMMCADMCA-UHFFFAOYSA-N 0.000 description 1
- UAJRCXRXJMBRNQ-UHFFFAOYSA-N 2-(2-oxo-4-thiophen-3-ylpiperidin-1-yl)butanamide Chemical compound C1C(=O)N(C(CC)C(N)=O)CCC1C1=CSC=C1 UAJRCXRXJMBRNQ-UHFFFAOYSA-N 0.000 description 1
- WKRZPPXQEKYMDA-UHFFFAOYSA-N 2-(2-oxo-5-phenylazepan-1-yl)butanamide Chemical compound C1CC(=O)N(C(CC)C(N)=O)CCC1C1=CC=CC=C1 WKRZPPXQEKYMDA-UHFFFAOYSA-N 0.000 description 1
- SBDLBPJRBGXZNB-UHFFFAOYSA-N 2-(2-oxo-5-prop-1-ynylazepan-1-yl)butanamide Chemical compound CCC(C(N)=O)N1CCC(C#CC)CCC1=O SBDLBPJRBGXZNB-UHFFFAOYSA-N 0.000 description 1
- LCKWQTLKCLFJCR-UHFFFAOYSA-N 2-(2-oxo-5-prop-1-ynylpiperidin-1-yl)butanamide Chemical compound CCC(C(N)=O)N1CC(C#CC)CCC1=O LCKWQTLKCLFJCR-UHFFFAOYSA-N 0.000 description 1
- GHGKIONLZRDMEB-UHFFFAOYSA-N 2-(2-oxo-5-propan-2-yl-3h-indol-1-yl)acetamide Chemical compound CC(C)C1=CC=C2N(CC(N)=O)C(=O)CC2=C1 GHGKIONLZRDMEB-UHFFFAOYSA-N 0.000 description 1
- LCMLGIBRWRIDCX-UHFFFAOYSA-N 2-(2-oxo-5-propyl-3h-indol-1-yl)acetamide Chemical compound CCCC1=CC=C2N(CC(N)=O)C(=O)CC2=C1 LCMLGIBRWRIDCX-UHFFFAOYSA-N 0.000 description 1
- MZQXMKLBYJBEGA-UHFFFAOYSA-N 2-(2-oxo-5-propylazepan-1-yl)butanamide Chemical compound CCCC1CCN(C(CC)C(N)=O)C(=O)CC1 MZQXMKLBYJBEGA-UHFFFAOYSA-N 0.000 description 1
- CJEPVJOSVZDHQV-UHFFFAOYSA-N 2-(2-oxo-5-propylpiperidin-1-yl)butanamide Chemical compound CCCC1CCC(=O)N(C(CC)C(N)=O)C1 CJEPVJOSVZDHQV-UHFFFAOYSA-N 0.000 description 1
- LXVNPFMMQYBAAL-UHFFFAOYSA-N 2-(2-oxo-5-thiophen-2-ylazepan-1-yl)butanamide Chemical compound C1CC(=O)N(C(CC)C(N)=O)CCC1C1=CC=CS1 LXVNPFMMQYBAAL-UHFFFAOYSA-N 0.000 description 1
- UIPAKYVDIDHWPQ-UHFFFAOYSA-N 2-(2-oxo-5-thiophen-2-ylpiperidin-1-yl)butanamide Chemical compound C1CC(=O)N(C(CC)C(N)=O)CC1C1=CC=CS1 UIPAKYVDIDHWPQ-UHFFFAOYSA-N 0.000 description 1
- KZCINCXVUOSPOD-UHFFFAOYSA-N 2-(2-oxo-5-thiophen-3-ylazepan-1-yl)butanamide Chemical compound C1CC(=O)N(C(CC)C(N)=O)CCC1C1=CSC=C1 KZCINCXVUOSPOD-UHFFFAOYSA-N 0.000 description 1
- BLOGBYGEHAWNOS-UHFFFAOYSA-N 2-(2-oxo-5-thiophen-3-ylpiperidin-1-yl)butanamide Chemical compound C1CC(=O)N(C(CC)C(N)=O)CC1C1=CSC=C1 BLOGBYGEHAWNOS-UHFFFAOYSA-N 0.000 description 1
- XYAXPQZHIIXPPD-UHFFFAOYSA-N 2-(2-oxo-6-phenylazepan-1-yl)butanamide Chemical compound C1CCC(=O)N(C(CC)C(N)=O)CC1C1=CC=CC=C1 XYAXPQZHIIXPPD-UHFFFAOYSA-N 0.000 description 1
- YEGLVNRDHDAQFL-UHFFFAOYSA-N 2-(2-oxo-6-prop-1-ynylazepan-1-yl)butanamide Chemical compound CCC(C(N)=O)N1CC(C#CC)CCCC1=O YEGLVNRDHDAQFL-UHFFFAOYSA-N 0.000 description 1
- DRUSYAAHFIZWOQ-UHFFFAOYSA-N 2-(2-oxo-6-propylazepan-1-yl)butanamide Chemical compound CCCC1CCCC(=O)N(C(CC)C(N)=O)C1 DRUSYAAHFIZWOQ-UHFFFAOYSA-N 0.000 description 1
- GMBFAMCTBBBELW-UHFFFAOYSA-N 2-(2-oxo-6-thiophen-2-ylazepan-1-yl)butanamide Chemical compound C1CCC(=O)N(C(CC)C(N)=O)CC1C1=CC=CS1 GMBFAMCTBBBELW-UHFFFAOYSA-N 0.000 description 1
- OFEHPEFFGCKBGV-UHFFFAOYSA-N 2-(2-oxo-6-thiophen-3-ylazepan-1-yl)butanamide Chemical compound C1CCC(=O)N(C(CC)C(N)=O)CC1C1=CSC=C1 OFEHPEFFGCKBGV-UHFFFAOYSA-N 0.000 description 1
- BKLQVZWYDUBJKM-UHFFFAOYSA-N 2-(4-but-1-ynyl-2-oxoazepan-1-yl)butanamide Chemical compound CCC#CC1CCCN(C(CC)C(N)=O)C(=O)C1 BKLQVZWYDUBJKM-UHFFFAOYSA-N 0.000 description 1
- VKJANVJSFZGOEZ-UHFFFAOYSA-N 2-(4-but-1-ynyl-2-oxopiperidin-1-yl)butanamide Chemical compound CCC#CC1CCN(C(CC)C(N)=O)C(=O)C1 VKJANVJSFZGOEZ-UHFFFAOYSA-N 0.000 description 1
- UCIPJTHORYWABM-UHFFFAOYSA-N 2-(4-butyl-2-oxopyrrolidin-1-yl)butanamide Chemical compound CCCCC1CN(C(CC)C(N)=O)C(=O)C1 UCIPJTHORYWABM-UHFFFAOYSA-N 0.000 description 1
- RYZZRHSVRMVUDL-UHFFFAOYSA-N 2-(4-ethenyl-2-oxopyrrolidin-1-yl)butanamide Chemical compound CCC(C(N)=O)N1CC(C=C)CC1=O RYZZRHSVRMVUDL-UHFFFAOYSA-N 0.000 description 1
- CAKZJIMVGRCBMP-UHFFFAOYSA-N 2-(4-ethynyl-2-oxoazepan-1-yl)butanamide Chemical compound CCC(C(N)=O)N1CCCC(C#C)CC1=O CAKZJIMVGRCBMP-UHFFFAOYSA-N 0.000 description 1
- IRKXEMOMPSWVES-UHFFFAOYSA-N 2-(4-ethynyl-2-oxopiperidin-1-yl)butanamide Chemical compound CCC(C(N)=O)N1CCC(C#C)CC1=O IRKXEMOMPSWVES-UHFFFAOYSA-N 0.000 description 1
- NLVDSLZEVKVXBN-UHFFFAOYSA-N 2-(4-ethynyl-2-oxopyrrolidin-1-yl)butanamide Chemical compound CCC(C(N)=O)N1CC(C#C)CC1=O NLVDSLZEVKVXBN-UHFFFAOYSA-N 0.000 description 1
- HPFWZQSNRKEGCA-UHFFFAOYSA-N 2-(5,6-dimethyl-2-oxo-3h-indol-1-yl)acetamide Chemical compound C1=C(C)C(C)=CC2=C1N(CC(N)=O)C(=O)C2 HPFWZQSNRKEGCA-UHFFFAOYSA-N 0.000 description 1
- LGNROFOLPFDIBL-UHFFFAOYSA-N 2-(5,7-dimethyl-2-oxo-3h-indol-1-yl)acetamide Chemical compound CC1=CC(C)=CC2=C1N(CC(N)=O)C(=O)C2 LGNROFOLPFDIBL-UHFFFAOYSA-N 0.000 description 1
- CMXAYTHGDJEUBI-UHFFFAOYSA-N 2-(5-bromo-2-oxo-3h-indol-1-yl)acetamide Chemical compound BrC1=CC=C2N(CC(=O)N)C(=O)CC2=C1 CMXAYTHGDJEUBI-UHFFFAOYSA-N 0.000 description 1
- KLKMLNUIWRFWPO-UHFFFAOYSA-N 2-(5-but-1-ynyl-2-oxoazepan-1-yl)butanamide Chemical compound CCC#CC1CCN(C(CC)C(N)=O)C(=O)CC1 KLKMLNUIWRFWPO-UHFFFAOYSA-N 0.000 description 1
- UWNUEBUFEDOFAH-UHFFFAOYSA-N 2-(5-but-1-ynyl-2-oxopiperidin-1-yl)butanamide Chemical compound CCC#CC1CCC(=O)N(C(CC)C(N)=O)C1 UWNUEBUFEDOFAH-UHFFFAOYSA-N 0.000 description 1
- HRLHPQWUBBPHHK-UHFFFAOYSA-N 2-(5-chloro-2-oxo-3h-indol-1-yl)-n-(1-hydroxybutan-2-yl)acetamide Chemical compound ClC1=CC=C2N(CC(=O)NC(CO)CC)C(=O)CC2=C1 HRLHPQWUBBPHHK-UHFFFAOYSA-N 0.000 description 1
- FVNKHNQDIGNNRA-UHFFFAOYSA-N 2-(5-chloro-2-oxo-3h-indol-1-yl)-n-(1h-1,2,4-triazol-5-yl)acetamide Chemical compound O=C1CC2=CC(Cl)=CC=C2N1CC(=O)NC1=NN=CN1 FVNKHNQDIGNNRA-UHFFFAOYSA-N 0.000 description 1
- AYYSGNHRZQOMHQ-UHFFFAOYSA-N 2-(5-chloro-2-oxo-3h-indol-1-yl)-n-(2-fluoroethyl)acetamide Chemical compound ClC1=CC=C2N(CC(=O)NCCF)C(=O)CC2=C1 AYYSGNHRZQOMHQ-UHFFFAOYSA-N 0.000 description 1
- ZUKFOQYUVXPDCB-UHFFFAOYSA-N 2-(5-chloro-2-oxo-3h-indol-1-yl)-n-(2-hydroxy-2-phenylethyl)acetamide Chemical compound O=C1CC2=CC(Cl)=CC=C2N1CC(=O)NCC(O)C1=CC=CC=C1 ZUKFOQYUVXPDCB-UHFFFAOYSA-N 0.000 description 1
- SEDQNQHXSZBTCP-UHFFFAOYSA-N 2-(5-chloro-2-oxo-3h-indol-1-yl)-n-(3,3,3-trifluoro-2-hydroxypropyl)acetamide Chemical compound ClC1=CC=C2N(CC(=O)NCC(O)C(F)(F)F)C(=O)CC2=C1 SEDQNQHXSZBTCP-UHFFFAOYSA-N 0.000 description 1
- KHQFYGKXNFSRCE-UHFFFAOYSA-N 2-(5-chloro-2-oxo-3h-indol-1-yl)-n-(3,4-dimethylphenyl)acetamide Chemical compound C1=C(C)C(C)=CC=C1NC(=O)CN1C2=CC=C(Cl)C=C2CC1=O KHQFYGKXNFSRCE-UHFFFAOYSA-N 0.000 description 1
- KEJUOQFROLNSMS-UHFFFAOYSA-N 2-(5-chloro-2-oxo-3h-indol-1-yl)-n-(3-ethoxypropyl)acetamide Chemical compound ClC1=CC=C2N(CC(=O)NCCCOCC)C(=O)CC2=C1 KEJUOQFROLNSMS-UHFFFAOYSA-N 0.000 description 1
- ZCCDYRIGAHXIEL-UHFFFAOYSA-N 2-(5-chloro-2-oxo-3h-indol-1-yl)-n-(3-hydroxy-2,2-dimethylpropyl)acetamide Chemical compound ClC1=CC=C2N(CC(=O)NCC(C)(CO)C)C(=O)CC2=C1 ZCCDYRIGAHXIEL-UHFFFAOYSA-N 0.000 description 1
- UXPDDILSJYZQRB-UHFFFAOYSA-N 2-(5-chloro-2-oxo-3h-indol-1-yl)-n-(3-hydroxyphenyl)acetamide Chemical compound OC1=CC=CC(NC(=O)CN2C3=CC=C(Cl)C=C3CC2=O)=C1 UXPDDILSJYZQRB-UHFFFAOYSA-N 0.000 description 1
- JBVPAJOGPBKJEP-UHFFFAOYSA-N 2-(5-chloro-2-oxo-3h-indol-1-yl)-n-(3-hydroxypropyl)acetamide Chemical compound ClC1=CC=C2N(CC(=O)NCCCO)C(=O)CC2=C1 JBVPAJOGPBKJEP-UHFFFAOYSA-N 0.000 description 1
- OCQROVSXKVOLOG-UHFFFAOYSA-N 2-(5-chloro-2-oxo-3h-indol-1-yl)-n-(6-methoxypyridin-3-yl)acetamide Chemical compound C1=NC(OC)=CC=C1NC(=O)CN1C2=CC=C(Cl)C=C2CC1=O OCQROVSXKVOLOG-UHFFFAOYSA-N 0.000 description 1
- FNRWXPBWWXEZPF-UHFFFAOYSA-N 2-(5-chloro-2-oxo-3h-indol-1-yl)-n-(oxolan-2-ylmethyl)-n-(pyridin-4-ylmethyl)acetamide Chemical compound O=C1CC2=CC(Cl)=CC=C2N1CC(=O)N(CC=1C=CN=CC=1)CC1CCCO1 FNRWXPBWWXEZPF-UHFFFAOYSA-N 0.000 description 1
- YCHIAOZIOKWROF-UHFFFAOYSA-N 2-(5-chloro-2-oxo-3h-indol-1-yl)-n-[(4-hydroxy-3-methoxyphenyl)methyl]acetamide Chemical compound C1=C(O)C(OC)=CC(CNC(=O)CN2C3=CC=C(Cl)C=C3CC2=O)=C1 YCHIAOZIOKWROF-UHFFFAOYSA-N 0.000 description 1
- JJLCZYXGGZBZNX-UHFFFAOYSA-N 2-(5-chloro-2-oxo-3h-indol-1-yl)-n-[(4-methylsulfonylphenyl)methyl]acetamide Chemical compound C1=CC(S(=O)(=O)C)=CC=C1CNC(=O)CN1C2=CC=C(Cl)C=C2CC1=O JJLCZYXGGZBZNX-UHFFFAOYSA-N 0.000 description 1
- XNXSULUCLLIMAC-UHFFFAOYSA-N 2-(5-chloro-2-oxo-3h-indol-1-yl)-n-[2-(2-methylpiperidin-1-yl)ethyl]acetamide Chemical compound CC1CCCCN1CCNC(=O)CN1C2=CC=C(Cl)C=C2CC1=O XNXSULUCLLIMAC-UHFFFAOYSA-N 0.000 description 1
- FJBYKKCZDPOKHR-UHFFFAOYSA-N 2-(5-chloro-2-oxo-3h-indol-1-yl)-n-[2-(3,4,5,6-tetrahydro-2h-1-benzazocin-1-yl)propyl]acetamide Chemical compound C1CCCCC2=CC=CC=C2N1C(C)CNC(=O)CN1C2=CC=C(Cl)C=C2CC1=O FJBYKKCZDPOKHR-UHFFFAOYSA-N 0.000 description 1
- RAXNMIDNCQXNPH-UHFFFAOYSA-N 2-(5-chloro-2-oxo-3h-indol-1-yl)-n-[2-(4-methylphenyl)ethyl]acetamide Chemical compound C1=CC(C)=CC=C1CCNC(=O)CN1C2=CC=C(Cl)C=C2CC1=O RAXNMIDNCQXNPH-UHFFFAOYSA-N 0.000 description 1
- RDQUHNGLGHXMQA-UHFFFAOYSA-N 2-(5-chloro-2-oxo-3h-indol-1-yl)-n-[3-(dimethylamino)propyl]acetamide Chemical compound ClC1=CC=C2N(CC(=O)NCCCN(C)C)C(=O)CC2=C1 RDQUHNGLGHXMQA-UHFFFAOYSA-N 0.000 description 1
- NDPGRWJKCWIQHS-UHFFFAOYSA-N 2-(5-chloro-2-oxo-3h-indol-1-yl)-n-[6-(hydroxymethyl)cyclohex-3-en-1-yl]acetamide Chemical compound OCC1CC=CCC1NC(=O)CN1C2=CC=C(Cl)C=C2CC1=O NDPGRWJKCWIQHS-UHFFFAOYSA-N 0.000 description 1
- BBQKWVUPPXPGRV-UHFFFAOYSA-N 2-(5-chloro-2-oxo-3h-indol-1-yl)-n-[[2-(trifluoromethylsulfanyl)phenyl]methyl]acetamide Chemical compound FC(F)(F)SC1=CC=CC=C1CNC(=O)CN1C2=CC=C(Cl)C=C2CC1=O BBQKWVUPPXPGRV-UHFFFAOYSA-N 0.000 description 1
- HWOGZQLVQPPPLW-UHFFFAOYSA-N 2-(5-chloro-2-oxo-3h-indol-1-yl)-n-methoxy-n-methylacetamide Chemical compound ClC1=CC=C2N(CC(=O)N(C)OC)C(=O)CC2=C1 HWOGZQLVQPPPLW-UHFFFAOYSA-N 0.000 description 1
- YCOAHBHANFIXAL-UHFFFAOYSA-N 2-(5-chloro-2-oxo-3h-indol-1-yl)-n-pyridin-3-ylacetamide Chemical compound O=C1CC2=CC(Cl)=CC=C2N1CC(=O)NC1=CC=CN=C1 YCOAHBHANFIXAL-UHFFFAOYSA-N 0.000 description 1
- IKNSJXRQZULJEQ-UHFFFAOYSA-N 2-(5-chloro-7-fluoro-2-oxo-3h-indol-1-yl)acetamide Chemical compound ClC1=CC(F)=C2N(CC(=O)N)C(=O)CC2=C1 IKNSJXRQZULJEQ-UHFFFAOYSA-N 0.000 description 1
- QWRCPMGIFHCLJI-UHFFFAOYSA-N 2-(5-ethyl-2-oxo-3h-indol-1-yl)acetamide Chemical compound CCC1=CC=C2N(CC(N)=O)C(=O)CC2=C1 QWRCPMGIFHCLJI-UHFFFAOYSA-N 0.000 description 1
- CZITUOJIRWGMMX-UHFFFAOYSA-N 2-(5-ethynyl-2-oxoazepan-1-yl)butanamide Chemical compound CCC(C(N)=O)N1CCC(C#C)CCC1=O CZITUOJIRWGMMX-UHFFFAOYSA-N 0.000 description 1
- LPGRGPZXTNGIFE-UHFFFAOYSA-N 2-(5-ethynyl-2-oxopiperidin-1-yl)butanamide Chemical compound CCC(C(N)=O)N1CC(C#C)CCC1=O LPGRGPZXTNGIFE-UHFFFAOYSA-N 0.000 description 1
- BJPAOGSIZOBUJM-UHFFFAOYSA-N 2-(5-fluoro-2-oxo-3h-indol-1-yl)acetamide Chemical compound FC1=CC=C2N(CC(=O)N)C(=O)CC2=C1 BJPAOGSIZOBUJM-UHFFFAOYSA-N 0.000 description 1
- PCYGBQKZTWTFKK-UHFFFAOYSA-N 2-(5-methyl-2-oxo-3h-indol-1-yl)acetamide Chemical compound CC1=CC=C2N(CC(N)=O)C(=O)CC2=C1 PCYGBQKZTWTFKK-UHFFFAOYSA-N 0.000 description 1
- SIBPXKGLOYCAHH-UHFFFAOYSA-N 2-(5-nitro-2-oxo-3h-indol-1-yl)acetamide Chemical compound [O-][N+](=O)C1=CC=C2N(CC(=O)N)C(=O)CC2=C1 SIBPXKGLOYCAHH-UHFFFAOYSA-N 0.000 description 1
- XVDAKCRGQYBQQD-UHFFFAOYSA-N 2-(6-but-1-ynyl-2-oxoazepan-1-yl)butanamide Chemical compound CCC#CC1CCCC(=O)N(C(CC)C(N)=O)C1 XVDAKCRGQYBQQD-UHFFFAOYSA-N 0.000 description 1
- DHWHMXNNAYYERX-UHFFFAOYSA-N 2-(6-chloro-2-oxo-3h-indol-1-yl)acetamide Chemical compound C1=C(Cl)C=C2N(CC(=O)N)C(=O)CC2=C1 DHWHMXNNAYYERX-UHFFFAOYSA-N 0.000 description 1
- DDYVVMIKQHHWGK-UHFFFAOYSA-N 2-(6-ethynyl-2-oxoazepan-1-yl)butanamide Chemical compound CCC(C(N)=O)N1CC(C#C)CCCC1=O DDYVVMIKQHHWGK-UHFFFAOYSA-N 0.000 description 1
- GWNMNEYLEQQDAE-UHFFFAOYSA-N 2-(7-butyl-3-methyl-2,6-dioxopurin-8-yl)sulfanylbutanamide Chemical compound CN1C(=O)NC(=O)C2=C1N=C(SC(CC)C(N)=O)N2CCCC GWNMNEYLEQQDAE-UHFFFAOYSA-N 0.000 description 1
- RGWBTXMIEAUHDV-UHFFFAOYSA-N 2-(7-chloro-2-oxo-3h-indol-1-yl)acetamide Chemical compound C1=CC(Cl)=C2N(CC(=O)N)C(=O)CC2=C1 RGWBTXMIEAUHDV-UHFFFAOYSA-N 0.000 description 1
- CLQMDQNDMBXQCU-JAMMHHFISA-N 2-[(4s)-4-(2,2-difluoropropyl)-2-oxopyrrolidin-1-yl]butanamide Chemical compound CCC(C(N)=O)N1C[C@H](CC(C)(F)F)CC1=O CLQMDQNDMBXQCU-JAMMHHFISA-N 0.000 description 1
- RNGWRLQTZHXISD-UHFFFAOYSA-N 2-[1-[(2-oxo-4-propylpyrrolidin-1-yl)methyl]benzimidazol-2-yl]acetonitrile Chemical compound O=C1CC(CCC)CN1CN1C2=CC=CC=C2N=C1CC#N RNGWRLQTZHXISD-UHFFFAOYSA-N 0.000 description 1
- DJSMBVDMRTYDPV-UHFFFAOYSA-N 2-[2-oxo-4-(1,3-thiazol-2-yl)pyrrolidin-1-yl]butanamide Chemical compound C1C(=O)N(C(CC)C(N)=O)CC1C1=NC=CS1 DJSMBVDMRTYDPV-UHFFFAOYSA-N 0.000 description 1
- CEJPTYNRARROLH-UHFFFAOYSA-N 2-[2-oxo-4-(3,3,3-trifluoroprop-1-ynyl)piperidin-1-yl]butanamide Chemical compound CCC(C(N)=O)N1CCC(C#CC(F)(F)F)CC1=O CEJPTYNRARROLH-UHFFFAOYSA-N 0.000 description 1
- QFQGHTLEORCHFL-UHFFFAOYSA-N 2-[2-oxo-4-(3,3,3-trifluoropropyl)piperidin-1-yl]butanamide Chemical compound CCC(C(N)=O)N1CCC(CCC(F)(F)F)CC1=O QFQGHTLEORCHFL-UHFFFAOYSA-N 0.000 description 1
- PNEZPRIKYVUDIR-UHFFFAOYSA-N 2-[2-oxo-4-[2-(trifluoromethyl)phenyl]pyrrolidin-1-yl]butanamide Chemical compound C1C(=O)N(C(CC)C(N)=O)CC1C1=CC=CC=C1C(F)(F)F PNEZPRIKYVUDIR-UHFFFAOYSA-N 0.000 description 1
- RFEIZQPIFWMMFG-UHFFFAOYSA-N 2-[2-oxo-5-(2,2,2-trifluoroethyl)azepan-1-yl]butanamide Chemical compound CCC(C(N)=O)N1CCC(CC(F)(F)F)CCC1=O RFEIZQPIFWMMFG-UHFFFAOYSA-N 0.000 description 1
- UJZRFAODZVHMQP-UHFFFAOYSA-N 2-[2-oxo-5-(3,3,3-trifluoroprop-1-ynyl)piperidin-1-yl]butanamide Chemical compound CCC(C(N)=O)N1CC(C#CC(F)(F)F)CCC1=O UJZRFAODZVHMQP-UHFFFAOYSA-N 0.000 description 1
- CWIHWYIXMJECAK-UHFFFAOYSA-N 2-[2-oxo-5-(3,3,3-trifluoropropyl)piperidin-1-yl]butanamide Chemical compound CCC(C(N)=O)N1CC(CCC(F)(F)F)CCC1=O CWIHWYIXMJECAK-UHFFFAOYSA-N 0.000 description 1
- JOFYXSGMXZPHMU-UHFFFAOYSA-N 2-[2-oxo-5-(trifluoromethoxy)-3h-indol-1-yl]acetamide Chemical compound FC(F)(F)OC1=CC=C2N(CC(=O)N)C(=O)CC2=C1 JOFYXSGMXZPHMU-UHFFFAOYSA-N 0.000 description 1
- ITBYJBZKSVFHMY-UHFFFAOYSA-N 2-[2-oxo-6-(3,3,3-trifluoropropyl)azepan-1-yl]butanamide Chemical compound CCC(C(N)=O)N1CC(CCC(F)(F)F)CCCC1=O ITBYJBZKSVFHMY-UHFFFAOYSA-N 0.000 description 1
- VRHOWPMSWLKCJP-UHFFFAOYSA-N 2-[4-(2,2-dibromoethenyl)-2-oxoazepan-1-yl]butanamide Chemical compound CCC(C(N)=O)N1CCCC(C=C(Br)Br)CC1=O VRHOWPMSWLKCJP-UHFFFAOYSA-N 0.000 description 1
- UNQPTZAWGPJZMS-UHFFFAOYSA-N 2-[4-(2,2-dibromoethenyl)-2-oxopiperidin-1-yl]butanamide Chemical compound CCC(C(N)=O)N1CCC(C=C(Br)Br)CC1=O UNQPTZAWGPJZMS-UHFFFAOYSA-N 0.000 description 1
- ZPKHWWVHQIJEIN-UHFFFAOYSA-N 2-[4-(2,2-dibromoethenyl)-2-oxopyrrolidin-1-yl]butanamide Chemical compound CCC(C(N)=O)N1CC(C=C(Br)Br)CC1=O ZPKHWWVHQIJEIN-UHFFFAOYSA-N 0.000 description 1
- ANRCNMMFFGLGNB-UHFFFAOYSA-N 2-[4-(2,2-dichloroethenyl)-2-oxoazepan-1-yl]butanamide Chemical compound CCC(C(N)=O)N1CCCC(C=C(Cl)Cl)CC1=O ANRCNMMFFGLGNB-UHFFFAOYSA-N 0.000 description 1
- NOKZIUZLJFIOTN-UHFFFAOYSA-N 2-[4-(2,2-dichloroethenyl)-2-oxopiperidin-1-yl]butanamide Chemical compound CCC(C(N)=O)N1CCC(C=C(Cl)Cl)CC1=O NOKZIUZLJFIOTN-UHFFFAOYSA-N 0.000 description 1
- CJLZTTGUJTZOHK-UHFFFAOYSA-N 2-[4-(2,2-difluoroethenyl)-2-oxoazepan-1-yl]butanamide Chemical compound CCC(C(N)=O)N1CCCC(C=C(F)F)CC1=O CJLZTTGUJTZOHK-UHFFFAOYSA-N 0.000 description 1
- WPADOWSQSALURJ-UHFFFAOYSA-N 2-[4-(2,2-difluoroethenyl)-2-oxopiperidin-1-yl]butanamide Chemical compound CCC(C(N)=O)N1CCC(C=C(F)F)CC1=O WPADOWSQSALURJ-UHFFFAOYSA-N 0.000 description 1
- ANWPENAPCIFDSZ-UHFFFAOYSA-N 2-[4-(2,2-difluoroethenyl)-2-oxopyrrolidin-1-yl]butanamide Chemical compound CCC(C(N)=O)N1CC(C=C(F)F)CC1=O ANWPENAPCIFDSZ-UHFFFAOYSA-N 0.000 description 1
- ZVVCDKBYFFNGMS-UHFFFAOYSA-N 2-[4-(2,2-difluoroethyl)-2-oxopyrrolidin-1-yl]butanamide Chemical compound CCC(C(N)=O)N1CC(CC(F)F)CC1=O ZVVCDKBYFFNGMS-UHFFFAOYSA-N 0.000 description 1
- CXXGOKJPFNCCJB-UHFFFAOYSA-N 2-[4-(2,2-difluoropropyl)-2-oxoazepan-1-yl]butanamide Chemical compound CCC(C(N)=O)N1CCCC(CC(C)(F)F)CC1=O CXXGOKJPFNCCJB-UHFFFAOYSA-N 0.000 description 1
- HQWPDSNULJZCQC-UHFFFAOYSA-N 2-[4-(2,2-difluoropropyl)-2-oxopiperidin-1-yl]butanamide Chemical compound CCC(C(N)=O)N1CCC(CC(C)(F)F)CC1=O HQWPDSNULJZCQC-UHFFFAOYSA-N 0.000 description 1
- SIINUMCWSCWIFL-UHFFFAOYSA-N 2-[4-(2,4-dichlorophenyl)-2-oxopyrrolidin-1-yl]butanamide Chemical compound C1C(=O)N(C(CC)C(N)=O)CC1C1=CC=C(Cl)C=C1Cl SIINUMCWSCWIFL-UHFFFAOYSA-N 0.000 description 1
- WGRNKMFWXJKFEJ-UHFFFAOYSA-N 2-[4-(2-bromo-2,2-difluoroethyl)-2-oxoazepan-1-yl]butanamide Chemical compound CCC(C(N)=O)N1CCCC(CC(F)(F)Br)CC1=O WGRNKMFWXJKFEJ-UHFFFAOYSA-N 0.000 description 1
- KLVVTSOYFSTMQR-UHFFFAOYSA-N 2-[4-(2-bromo-2,2-difluoroethyl)-2-oxopiperidin-1-yl]butanamide Chemical compound CCC(C(N)=O)N1CCC(CC(F)(F)Br)CC1=O KLVVTSOYFSTMQR-UHFFFAOYSA-N 0.000 description 1
- GYMMJGNIZFXYQD-UHFFFAOYSA-N 2-[4-(2-bromoethynyl)-2-oxopyrrolidin-1-yl]butanamide Chemical compound CCC(C(N)=O)N1CC(C#CBr)CC1=O GYMMJGNIZFXYQD-UHFFFAOYSA-N 0.000 description 1
- CMGYTWWVFFCIAP-UHFFFAOYSA-N 2-[4-(2-bromophenyl)-2-oxopyrrolidin-1-yl]butanamide Chemical compound C1C(=O)N(C(CC)C(N)=O)CC1C1=CC=CC=C1Br CMGYTWWVFFCIAP-UHFFFAOYSA-N 0.000 description 1
- NAWJROXSTSGQQJ-UHFFFAOYSA-N 2-[4-(2-chloro-2,2-difluoroethyl)-2-oxopiperidin-1-yl]butanamide Chemical compound CCC(C(N)=O)N1CCC(CC(F)(F)Cl)CC1=O NAWJROXSTSGQQJ-UHFFFAOYSA-N 0.000 description 1
- YEITVUMXKXDAHM-UHFFFAOYSA-N 2-[4-(2-cyclopropylethynyl)-2-oxoazepan-1-yl]butanamide Chemical compound C1C(=O)N(C(CC)C(N)=O)CCCC1C#CC1CC1 YEITVUMXKXDAHM-UHFFFAOYSA-N 0.000 description 1
- CMFNDKZENTVWKI-UHFFFAOYSA-N 2-[4-(2-cyclopropylethynyl)-2-oxopiperidin-1-yl]butanamide Chemical compound C1C(=O)N(C(CC)C(N)=O)CCC1C#CC1CC1 CMFNDKZENTVWKI-UHFFFAOYSA-N 0.000 description 1
- XLLLPDNWHVCILR-UHFFFAOYSA-N 2-[4-(2-methylprop-1-enyl)-2-oxopyrrolidin-1-yl]butanamide Chemical compound CCC(C(N)=O)N1CC(C=C(C)C)CC1=O XLLLPDNWHVCILR-UHFFFAOYSA-N 0.000 description 1
- VNOVLVOAZZCYOX-UHFFFAOYSA-N 2-[4-(2-methylpropyl)-2-oxopyrrolidin-1-yl]butanamide Chemical compound CCC(C(N)=O)N1CC(CC(C)C)CC1=O VNOVLVOAZZCYOX-UHFFFAOYSA-N 0.000 description 1
- JJYJAEYXZPKPTD-UHFFFAOYSA-N 2-[4-(3-azidophenyl)-2-oxoazepan-1-yl]butanamide Chemical compound C1C(=O)N(C(CC)C(N)=O)CCCC1C1=CC=CC(N=[N+]=[N-])=C1 JJYJAEYXZPKPTD-UHFFFAOYSA-N 0.000 description 1
- OROOBVNLHLCNJJ-UHFFFAOYSA-N 2-[4-(3-azidophenyl)-2-oxopiperidin-1-yl]butanamide Chemical compound C1C(=O)N(C(CC)C(N)=O)CCC1C1=CC=CC(N=[N+]=[N-])=C1 OROOBVNLHLCNJJ-UHFFFAOYSA-N 0.000 description 1
- PYPZPCVWOFFMOL-UHFFFAOYSA-N 2-[4-(3-bromothiophen-2-yl)-2-oxoazepan-1-yl]butanamide Chemical compound C1C(=O)N(C(CC)C(N)=O)CCCC1C1=C(Br)C=CS1 PYPZPCVWOFFMOL-UHFFFAOYSA-N 0.000 description 1
- IAJZJIQTZHWMSE-UHFFFAOYSA-N 2-[4-(3-bromothiophen-2-yl)-2-oxopiperidin-1-yl]butanamide Chemical compound C1C(=O)N(C(CC)C(N)=O)CCC1C1=C(Br)C=CS1 IAJZJIQTZHWMSE-UHFFFAOYSA-N 0.000 description 1
- LNWTZLNGQXQBQZ-UHFFFAOYSA-N 2-[4-(3-chlorophenyl)-2-oxoazepan-1-yl]butanamide Chemical compound C1C(=O)N(C(CC)C(N)=O)CCCC1C1=CC=CC(Cl)=C1 LNWTZLNGQXQBQZ-UHFFFAOYSA-N 0.000 description 1
- ZBHNNQGBHCQUGF-UHFFFAOYSA-N 2-[4-(3-chlorophenyl)-2-oxopiperidin-1-yl]butanamide Chemical compound C1C(=O)N(C(CC)C(N)=O)CCC1C1=CC=CC(Cl)=C1 ZBHNNQGBHCQUGF-UHFFFAOYSA-N 0.000 description 1
- PKIMYEYTMHHFKV-UHFFFAOYSA-N 2-[4-(3-methylbut-1-ynyl)-2-oxoazepan-1-yl]butanamide Chemical compound CCC(C(N)=O)N1CCCC(C#CC(C)C)CC1=O PKIMYEYTMHHFKV-UHFFFAOYSA-N 0.000 description 1
- ILEJMEWSBMQBQI-UHFFFAOYSA-N 2-[4-(3-methylbut-1-ynyl)-2-oxopiperidin-1-yl]butanamide Chemical compound CCC(C(N)=O)N1CCC(C#CC(C)C)CC1=O ILEJMEWSBMQBQI-UHFFFAOYSA-N 0.000 description 1
- VJQZFHLIVWLRFO-UHFFFAOYSA-N 2-[4-(4-chlorophenyl)-2-oxopyrrolidin-1-yl]butanamide Chemical compound C1C(=O)N(C(CC)C(N)=O)CC1C1=CC=C(Cl)C=C1 VJQZFHLIVWLRFO-UHFFFAOYSA-N 0.000 description 1
- BKXXXWMYOVWCJU-UHFFFAOYSA-N 2-[4-(4-methylthiophen-2-yl)-2-oxoazepan-1-yl]butanamide Chemical compound C1C(=O)N(C(CC)C(N)=O)CCCC1C1=CC(C)=CS1 BKXXXWMYOVWCJU-UHFFFAOYSA-N 0.000 description 1
- DQFNHSAIBNECIM-UHFFFAOYSA-N 2-[4-(4-methylthiophen-2-yl)-2-oxopiperidin-1-yl]butanamide Chemical compound C1C(=O)N(C(CC)C(N)=O)CCC1C1=CC(C)=CS1 DQFNHSAIBNECIM-UHFFFAOYSA-N 0.000 description 1
- HQLCAQPWSYUMQK-UHFFFAOYSA-N 2-[4-(5-cyanothiophen-2-yl)-2-oxopiperidin-1-yl]butanamide Chemical compound C1C(=O)N(C(CC)C(N)=O)CCC1C1=CC=C(C#N)S1 HQLCAQPWSYUMQK-UHFFFAOYSA-N 0.000 description 1
- PRYNMXCUCQXUHF-UHFFFAOYSA-N 2-[4-(5-formylthiophen-2-yl)-2-oxoazepan-1-yl]butanamide Chemical compound C1C(=O)N(C(CC)C(N)=O)CCCC1C1=CC=C(C=O)S1 PRYNMXCUCQXUHF-UHFFFAOYSA-N 0.000 description 1
- BPBNSWUQAMDOIY-UHFFFAOYSA-N 2-[4-(5-formylthiophen-2-yl)-2-oxopiperidin-1-yl]butanamide Chemical compound C1C(=O)N(C(CC)C(N)=O)CCC1C1=CC=C(C=O)S1 BPBNSWUQAMDOIY-UHFFFAOYSA-N 0.000 description 1
- YDEJQSQCVGSEJA-UHFFFAOYSA-N 2-[4-(5-methylthiophen-2-yl)-2-oxoazepan-1-yl]butanamide Chemical compound C1C(=O)N(C(CC)C(N)=O)CCCC1C1=CC=C(C)S1 YDEJQSQCVGSEJA-UHFFFAOYSA-N 0.000 description 1
- PMISDOUIMNQVIW-UHFFFAOYSA-N 2-[4-(5-methylthiophen-2-yl)-2-oxopiperidin-1-yl]butanamide Chemical compound C1C(=O)N(C(CC)C(N)=O)CCC1C1=CC=C(C)S1 PMISDOUIMNQVIW-UHFFFAOYSA-N 0.000 description 1
- GYOSDRQZBHCDQV-UHFFFAOYSA-N 2-[4-(azidomethyl)-2-oxoazepan-1-yl]butanamide Chemical compound CCC(C(N)=O)N1CCCC(CN=[N+]=[N-])CC1=O GYOSDRQZBHCDQV-UHFFFAOYSA-N 0.000 description 1
- MULKDPRXSMORGR-UHFFFAOYSA-N 2-[4-(azidomethyl)-2-oxopiperidin-1-yl]butanamide Chemical compound CCC(C(N)=O)N1CCC(CN=[N+]=[N-])CC1=O MULKDPRXSMORGR-UHFFFAOYSA-N 0.000 description 1
- FBXBRZAZFGMSJY-UHFFFAOYSA-N 2-[4-(cyclopropylmethyl)-2-oxoazepan-1-yl]butanamide Chemical compound C1C(=O)N(C(CC)C(N)=O)CCCC1CC1CC1 FBXBRZAZFGMSJY-UHFFFAOYSA-N 0.000 description 1
- QWGOSPMNEKTQTO-UHFFFAOYSA-N 2-[4-(cyclopropylmethyl)-2-oxopiperidin-1-yl]butanamide Chemical compound C1C(=O)N(C(CC)C(N)=O)CCC1CC1CC1 QWGOSPMNEKTQTO-UHFFFAOYSA-N 0.000 description 1
- IHYNOEHNHISISC-UHFFFAOYSA-N 2-[4-(cyclopropylmethyl)-2-oxopyrrolidin-1-yl]butanamide Chemical compound C1C(=O)N(C(CC)C(N)=O)CC1CC1CC1 IHYNOEHNHISISC-UHFFFAOYSA-N 0.000 description 1
- IKTSRKOWAPDXDL-UHFFFAOYSA-N 2-[4-(furan-2-yl)-2-oxopyrrolidin-1-yl]butanamide Chemical compound C1C(=O)N(C(CC)C(N)=O)CC1C1=CC=CO1 IKTSRKOWAPDXDL-UHFFFAOYSA-N 0.000 description 1
- XIUPTTMFZRHBOS-UHFFFAOYSA-N 2-[4-(hydroxymethyl)-2-oxoazepan-1-yl]butanamide Chemical compound CCC(C(N)=O)N1CCCC(CO)CC1=O XIUPTTMFZRHBOS-UHFFFAOYSA-N 0.000 description 1
- RCXAYMQABDOGQG-UHFFFAOYSA-N 2-[4-(hydroxymethyl)-2-oxopiperidin-1-yl]butanamide Chemical compound CCC(C(N)=O)N1CCC(CO)CC1=O RCXAYMQABDOGQG-UHFFFAOYSA-N 0.000 description 1
- BMYPWXYOCDPEQQ-UHFFFAOYSA-N 2-[4-(iodomethyl)-2-oxoazepan-1-yl]butanamide Chemical compound CCC(C(N)=O)N1CCCC(CI)CC1=O BMYPWXYOCDPEQQ-UHFFFAOYSA-N 0.000 description 1
- PAMQVXOBQOEDRC-UHFFFAOYSA-N 2-[4-(iodomethyl)-2-oxopiperidin-1-yl]butanamide Chemical compound CCC(C(N)=O)N1CCC(CI)CC1=O PAMQVXOBQOEDRC-UHFFFAOYSA-N 0.000 description 1
- MUAFOMJSWIWBTJ-UHFFFAOYSA-N 2-[4-(iodomethyl)-2-oxopyrrolidin-1-yl]butanamide Chemical compound CCC(C(N)=O)N1CC(CI)CC1=O MUAFOMJSWIWBTJ-UHFFFAOYSA-N 0.000 description 1
- YLZPTPADBPEBPI-ARJAWSKDSA-N 2-[4-[(z)-2-fluoroethenyl]-2-oxopyrrolidin-1-yl]butanamide Chemical compound CCC(C(N)=O)N1CC(\C=C/F)CC1=O YLZPTPADBPEBPI-ARJAWSKDSA-N 0.000 description 1
- CYKQOGRIBMLQSQ-UHFFFAOYSA-N 2-[4-[3,5-bis(trifluoromethyl)phenyl]-2-oxopyrrolidin-1-yl]butanamide Chemical compound C1C(=O)N(C(CC)C(N)=O)CC1C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 CYKQOGRIBMLQSQ-UHFFFAOYSA-N 0.000 description 1
- MXHPUUKYIBGKFC-UHFFFAOYSA-N 2-[5-(2,2-dibromoethenyl)-2-oxoazepan-1-yl]butanamide Chemical compound CCC(C(N)=O)N1CCC(C=C(Br)Br)CCC1=O MXHPUUKYIBGKFC-UHFFFAOYSA-N 0.000 description 1
- PCWOAZOPMIUDAV-UHFFFAOYSA-N 2-[5-(2,2-dibromoethenyl)-2-oxopiperidin-1-yl]butanamide Chemical compound CCC(C(N)=O)N1CC(C=C(Br)Br)CCC1=O PCWOAZOPMIUDAV-UHFFFAOYSA-N 0.000 description 1
- LAUFIBMAXWIQDO-UHFFFAOYSA-N 2-[5-(2,2-dichloroethenyl)-2-oxoazepan-1-yl]butanamide Chemical compound CCC(C(N)=O)N1CCC(C=C(Cl)Cl)CCC1=O LAUFIBMAXWIQDO-UHFFFAOYSA-N 0.000 description 1
- FHUVJSDDGMIWKD-UHFFFAOYSA-N 2-[5-(2,2-dichloroethenyl)-2-oxopiperidin-1-yl]butanamide Chemical compound CCC(C(N)=O)N1CC(C=C(Cl)Cl)CCC1=O FHUVJSDDGMIWKD-UHFFFAOYSA-N 0.000 description 1
- RAOGPMVGOMSNJH-UHFFFAOYSA-N 2-[5-(2,2-difluoroethenyl)-2-oxoazepan-1-yl]butanamide Chemical compound CCC(C(N)=O)N1CCC(C=C(F)F)CCC1=O RAOGPMVGOMSNJH-UHFFFAOYSA-N 0.000 description 1
- OEQRTQKNXMNRQN-UHFFFAOYSA-N 2-[5-(2,2-difluoroethenyl)-2-oxopiperidin-1-yl]butanamide Chemical compound CCC(C(N)=O)N1CC(C=C(F)F)CCC1=O OEQRTQKNXMNRQN-UHFFFAOYSA-N 0.000 description 1
- FZCNEQAUEQNHMY-UHFFFAOYSA-N 2-[5-(2,2-difluoropropyl)-2-oxoazepan-1-yl]butanamide Chemical compound CCC(C(N)=O)N1CCC(CC(C)(F)F)CCC1=O FZCNEQAUEQNHMY-UHFFFAOYSA-N 0.000 description 1
- BRTOJNFZOSMNCS-UHFFFAOYSA-N 2-[5-(2,2-difluoropropyl)-2-oxopiperidin-1-yl]butanamide Chemical compound CCC(C(N)=O)N1CC(CC(C)(F)F)CCC1=O BRTOJNFZOSMNCS-UHFFFAOYSA-N 0.000 description 1
- CWZZAOLHXCFAEM-UHFFFAOYSA-N 2-[5-(2-bromo-2,2-difluoroethyl)-2-oxopiperidin-1-yl]butanamide Chemical compound CCC(C(N)=O)N1CC(CC(F)(F)Br)CCC1=O CWZZAOLHXCFAEM-UHFFFAOYSA-N 0.000 description 1
- STPBCHKCXPWVFF-UHFFFAOYSA-N 2-[5-(2-chloro-2,2-difluoroethyl)-2-oxopiperidin-1-yl]butanamide Chemical compound CCC(C(N)=O)N1CC(CC(F)(F)Cl)CCC1=O STPBCHKCXPWVFF-UHFFFAOYSA-N 0.000 description 1
- GAQOYSYEMZXJPW-UHFFFAOYSA-N 2-[5-(2-cyclopropylethynyl)-2-oxoazepan-1-yl]butanamide Chemical compound C1CC(=O)N(C(CC)C(N)=O)CCC1C#CC1CC1 GAQOYSYEMZXJPW-UHFFFAOYSA-N 0.000 description 1
- RTGNMUOMVBACMX-UHFFFAOYSA-N 2-[5-(2-cyclopropylethynyl)-2-oxopiperidin-1-yl]butanamide Chemical compound C1CC(=O)N(C(CC)C(N)=O)CC1C#CC1CC1 RTGNMUOMVBACMX-UHFFFAOYSA-N 0.000 description 1
- NNHYPLAJMUZDNQ-UHFFFAOYSA-N 2-[5-(3-azidophenyl)-2-oxoazepan-1-yl]butanamide Chemical compound C1CC(=O)N(C(CC)C(N)=O)CCC1C1=CC=CC(N=[N+]=[N-])=C1 NNHYPLAJMUZDNQ-UHFFFAOYSA-N 0.000 description 1
- CZEFBMZIEBDFMS-UHFFFAOYSA-N 2-[5-(3-azidophenyl)-2-oxopiperidin-1-yl]butanamide Chemical compound C1CC(=O)N(C(CC)C(N)=O)CC1C1=CC=CC(N=[N+]=[N-])=C1 CZEFBMZIEBDFMS-UHFFFAOYSA-N 0.000 description 1
- KQJSRDMUJMBTEV-UHFFFAOYSA-N 2-[5-(3-bromothiophen-2-yl)-2-oxoazepan-1-yl]butanamide Chemical compound C1CC(=O)N(C(CC)C(N)=O)CCC1C1=C(Br)C=CS1 KQJSRDMUJMBTEV-UHFFFAOYSA-N 0.000 description 1
- JATBTDNOGMGPCR-UHFFFAOYSA-N 2-[5-(3-bromothiophen-2-yl)-2-oxopiperidin-1-yl]butanamide Chemical compound C1CC(=O)N(C(CC)C(N)=O)CC1C1=C(Br)C=CS1 JATBTDNOGMGPCR-UHFFFAOYSA-N 0.000 description 1
- XDEXJFXTHCSDSV-UHFFFAOYSA-N 2-[5-(3-chlorophenyl)-2-oxoazepan-1-yl]butanamide Chemical compound C1CC(=O)N(C(CC)C(N)=O)CCC1C1=CC=CC(Cl)=C1 XDEXJFXTHCSDSV-UHFFFAOYSA-N 0.000 description 1
- HLAWZJPEZBHLKI-UHFFFAOYSA-N 2-[5-(3-chlorophenyl)-2-oxopiperidin-1-yl]butanamide Chemical compound C1CC(=O)N(C(CC)C(N)=O)CC1C1=CC=CC(Cl)=C1 HLAWZJPEZBHLKI-UHFFFAOYSA-N 0.000 description 1
- XCSJQTJRQGHZLP-UHFFFAOYSA-N 2-[5-(3-methylbut-1-ynyl)-2-oxoazepan-1-yl]butanamide Chemical compound CCC(C(N)=O)N1CCC(C#CC(C)C)CCC1=O XCSJQTJRQGHZLP-UHFFFAOYSA-N 0.000 description 1
- DBWMAAKXOXHJEW-UHFFFAOYSA-N 2-[5-(3-methylbut-1-ynyl)-2-oxopiperidin-1-yl]butanamide Chemical compound CCC(C(N)=O)N1CC(C#CC(C)C)CCC1=O DBWMAAKXOXHJEW-UHFFFAOYSA-N 0.000 description 1
- MBKMTYYXUITVGU-UHFFFAOYSA-N 2-[5-(4-methylthiophen-2-yl)-2-oxoazepan-1-yl]butanamide Chemical compound C1CC(=O)N(C(CC)C(N)=O)CCC1C1=CC(C)=CS1 MBKMTYYXUITVGU-UHFFFAOYSA-N 0.000 description 1
- IWQYIMUYGXISNT-UHFFFAOYSA-N 2-[5-(4-methylthiophen-2-yl)-2-oxopiperidin-1-yl]butanamide Chemical compound C1CC(=O)N(C(CC)C(N)=O)CC1C1=CC(C)=CS1 IWQYIMUYGXISNT-UHFFFAOYSA-N 0.000 description 1
- YTMOOOPLRBMUFU-UHFFFAOYSA-N 2-[5-(5-cyanothiophen-2-yl)-2-oxoazepan-1-yl]butanamide Chemical compound C1CC(=O)N(C(CC)C(N)=O)CCC1C1=CC=C(C#N)S1 YTMOOOPLRBMUFU-UHFFFAOYSA-N 0.000 description 1
- MDCOZWVROFJFAX-UHFFFAOYSA-N 2-[5-(5-cyanothiophen-2-yl)-2-oxopiperidin-1-yl]butanamide Chemical compound C1CC(=O)N(C(CC)C(N)=O)CC1C1=CC=C(C#N)S1 MDCOZWVROFJFAX-UHFFFAOYSA-N 0.000 description 1
- TYONZOOMGQORSB-UHFFFAOYSA-N 2-[5-(5-formylthiophen-2-yl)-2-oxoazepan-1-yl]butanamide Chemical compound C1CC(=O)N(C(CC)C(N)=O)CCC1C1=CC=C(C=O)S1 TYONZOOMGQORSB-UHFFFAOYSA-N 0.000 description 1
- GCXSLFDIKSXQSD-UHFFFAOYSA-N 2-[5-(5-formylthiophen-2-yl)-2-oxopiperidin-1-yl]butanamide Chemical compound C1CC(=O)N(C(CC)C(N)=O)CC1C1=CC=C(C=O)S1 GCXSLFDIKSXQSD-UHFFFAOYSA-N 0.000 description 1
- YEGAVGOWQJFHMQ-UHFFFAOYSA-N 2-[5-(5-methylthiophen-2-yl)-2-oxoazepan-1-yl]butanamide Chemical compound C1CC(=O)N(C(CC)C(N)=O)CCC1C1=CC=C(C)S1 YEGAVGOWQJFHMQ-UHFFFAOYSA-N 0.000 description 1
- WEUWXEUQDVBOBZ-UHFFFAOYSA-N 2-[5-(azidomethyl)-2-oxoazepan-1-yl]butanamide Chemical compound CCC(C(N)=O)N1CCC(CN=[N+]=[N-])CCC1=O WEUWXEUQDVBOBZ-UHFFFAOYSA-N 0.000 description 1
- XOFFNXIJSCUXQG-UHFFFAOYSA-N 2-[5-(azidomethyl)-2-oxopiperidin-1-yl]butanamide Chemical compound CCC(C(N)=O)N1CC(CN=[N+]=[N-])CCC1=O XOFFNXIJSCUXQG-UHFFFAOYSA-N 0.000 description 1
- ZMEFWWQEIQKFMU-UHFFFAOYSA-N 2-[5-(cyclopropylmethyl)-2-oxoazepan-1-yl]butanamide Chemical compound C1CC(=O)N(C(CC)C(N)=O)CCC1CC1CC1 ZMEFWWQEIQKFMU-UHFFFAOYSA-N 0.000 description 1
- CUXVDWHNLNOKIL-UHFFFAOYSA-N 2-[5-(cyclopropylmethyl)-2-oxopiperidin-1-yl]butanamide Chemical compound C1CC(=O)N(C(CC)C(N)=O)CC1CC1CC1 CUXVDWHNLNOKIL-UHFFFAOYSA-N 0.000 description 1
- HFHNNYCELLPNGN-UHFFFAOYSA-N 2-[5-(hydroxymethyl)-2-oxopiperidin-1-yl]butanamide Chemical compound CCC(C(N)=O)N1CC(CO)CCC1=O HFHNNYCELLPNGN-UHFFFAOYSA-N 0.000 description 1
- IBWLHPRXVHYPHR-UHFFFAOYSA-N 2-[5-(iodomethyl)-2-oxoazepan-1-yl]butanamide Chemical compound CCC(C(N)=O)N1CCC(CI)CCC1=O IBWLHPRXVHYPHR-UHFFFAOYSA-N 0.000 description 1
- UDKQJJFZWIUVFH-UHFFFAOYSA-N 2-[5-(iodomethyl)-2-oxopiperidin-1-yl]butanamide Chemical compound CCC(C(N)=O)N1CC(CI)CCC1=O UDKQJJFZWIUVFH-UHFFFAOYSA-N 0.000 description 1
- ATKNWYMGMPUAFA-UHFFFAOYSA-N 2-[6-(2,2-dibromoethenyl)-2-oxoazepan-1-yl]butanamide Chemical compound CCC(C(N)=O)N1CC(C=C(Br)Br)CCCC1=O ATKNWYMGMPUAFA-UHFFFAOYSA-N 0.000 description 1
- DWOQFIBQUMNZNJ-UHFFFAOYSA-N 2-[6-(2,2-dichloroethenyl)-2-oxoazepan-1-yl]butanamide Chemical compound CCC(C(N)=O)N1CC(C=C(Cl)Cl)CCCC1=O DWOQFIBQUMNZNJ-UHFFFAOYSA-N 0.000 description 1
- LRHYJSCLDHABAI-UHFFFAOYSA-N 2-[6-(2,2-difluoroethenyl)-2-oxoazepan-1-yl]butanamide Chemical compound CCC(C(N)=O)N1CC(C=C(F)F)CCCC1=O LRHYJSCLDHABAI-UHFFFAOYSA-N 0.000 description 1
- GFKZIJRROXVJSV-UHFFFAOYSA-N 2-[6-(2,2-difluoropropyl)-2-oxoazepan-1-yl]butanamide Chemical compound CCC(C(N)=O)N1CC(CC(C)(F)F)CCCC1=O GFKZIJRROXVJSV-UHFFFAOYSA-N 0.000 description 1
- VRRJNLKXFLQGLF-UHFFFAOYSA-N 2-[6-(2-bromo-2,2-difluoroethyl)-2-oxoazepan-1-yl]butanamide Chemical compound CCC(C(N)=O)N1CC(CC(F)(F)Br)CCCC1=O VRRJNLKXFLQGLF-UHFFFAOYSA-N 0.000 description 1
- IHSXBBNCXLZGCU-UHFFFAOYSA-N 2-[6-(2-cyclopropylethynyl)-2-oxoazepan-1-yl]butanamide Chemical compound C1CCC(=O)N(C(CC)C(N)=O)CC1C#CC1CC1 IHSXBBNCXLZGCU-UHFFFAOYSA-N 0.000 description 1
- GRNMQWJNFQPNLC-UHFFFAOYSA-N 2-[6-(3-azidophenyl)-2-oxoazepan-1-yl]butanamide Chemical compound C1CCC(=O)N(C(CC)C(N)=O)CC1C1=CC=CC(N=[N+]=[N-])=C1 GRNMQWJNFQPNLC-UHFFFAOYSA-N 0.000 description 1
- GREMTNQCYOASHJ-UHFFFAOYSA-N 2-[6-(3-bromothiophen-2-yl)-2-oxoazepan-1-yl]butanamide Chemical compound C1CCC(=O)N(C(CC)C(N)=O)CC1C1=C(Br)C=CS1 GREMTNQCYOASHJ-UHFFFAOYSA-N 0.000 description 1
- AYTJASLQBCHODN-UHFFFAOYSA-N 2-[6-(3-chlorophenyl)-2-oxoazepan-1-yl]butanamide Chemical compound C1CCC(=O)N(C(CC)C(N)=O)CC1C1=CC=CC(Cl)=C1 AYTJASLQBCHODN-UHFFFAOYSA-N 0.000 description 1
- ORFIMAXQBSKJHP-UHFFFAOYSA-N 2-[6-(3-methylbut-1-ynyl)-2-oxoazepan-1-yl]butanamide Chemical compound CCC(C(N)=O)N1CC(C#CC(C)C)CCCC1=O ORFIMAXQBSKJHP-UHFFFAOYSA-N 0.000 description 1
- XAXLABRVHJVBAH-UHFFFAOYSA-N 2-[6-(4-methylthiophen-2-yl)-2-oxoazepan-1-yl]butanamide Chemical compound C1CCC(=O)N(C(CC)C(N)=O)CC1C1=CC(C)=CS1 XAXLABRVHJVBAH-UHFFFAOYSA-N 0.000 description 1
- HJIGBFCJALOXDB-UHFFFAOYSA-N 2-[6-(5-cyanothiophen-2-yl)-2-oxoazepan-1-yl]butanamide Chemical compound C1CCC(=O)N(C(CC)C(N)=O)CC1C1=CC=C(C#N)S1 HJIGBFCJALOXDB-UHFFFAOYSA-N 0.000 description 1
- JIOYELBIIDWQSK-UHFFFAOYSA-N 2-[6-(5-formylthiophen-2-yl)-2-oxoazepan-1-yl]butanamide Chemical compound C1CCC(=O)N(C(CC)C(N)=O)CC1C1=CC=C(C=O)S1 JIOYELBIIDWQSK-UHFFFAOYSA-N 0.000 description 1
- OCLAGKXZEQFNMD-UHFFFAOYSA-N 2-[6-(5-methylthiophen-2-yl)-2-oxoazepan-1-yl]butanamide Chemical compound C1CCC(=O)N(C(CC)C(N)=O)CC1C1=CC=C(C)S1 OCLAGKXZEQFNMD-UHFFFAOYSA-N 0.000 description 1
- VFQDENLBDHEDHB-UHFFFAOYSA-N 2-[6-(cyclopropylmethyl)-2-oxoazepan-1-yl]butanamide Chemical compound C1CCC(=O)N(C(CC)C(N)=O)CC1CC1CC1 VFQDENLBDHEDHB-UHFFFAOYSA-N 0.000 description 1
- LGPINSRFCVWKRA-UHFFFAOYSA-N 2-[6-(hydroxymethyl)-2-oxoazepan-1-yl]butanamide Chemical compound CCC(C(N)=O)N1CC(CO)CCCC1=O LGPINSRFCVWKRA-UHFFFAOYSA-N 0.000 description 1
- SKBMSYROYUEAPU-UHFFFAOYSA-N 2-[6-(iodomethyl)-2-oxoazepan-1-yl]butanamide Chemical compound CCC(C(N)=O)N1CC(CI)CCCC1=O SKBMSYROYUEAPU-UHFFFAOYSA-N 0.000 description 1
- SZTLXSATMGILQF-UHFFFAOYSA-N 2-azido-1,3,5-trifluorobenzene Chemical compound FC1=CC(F)=C(N=[N+]=[N-])C(F)=C1 SZTLXSATMGILQF-UHFFFAOYSA-N 0.000 description 1
- 125000006276 2-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C(*)C([H])=C1[H] 0.000 description 1
- YQXCVVFSHVDWOZ-UHFFFAOYSA-N 2-butyl-1-[(2-oxo-4-propylpyrrolidin-1-yl)methyl]benzimidazole-5-carbonitrile Chemical compound CCCCC1=NC2=CC(C#N)=CC=C2N1CN1CC(CCC)CC1=O YQXCVVFSHVDWOZ-UHFFFAOYSA-N 0.000 description 1
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 1
- OTZAWWUGHCVKAS-UHFFFAOYSA-N 2-cyclopropyl-1-[(2-oxo-4-propylpyrrolidin-1-yl)methyl]benzimidazole-5-carbonitrile Chemical compound O=C1CC(CCC)CN1CN1C2=CC=C(C#N)C=C2N=C1C1CC1 OTZAWWUGHCVKAS-UHFFFAOYSA-N 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 1
- JSLASWSJHUAUMT-UHFFFAOYSA-N 2H-tetrazol-5-yl benzenesulfonate Chemical compound C=1C=CC=CC=1S(=O)(=O)OC1=NN=NN1 JSLASWSJHUAUMT-UHFFFAOYSA-N 0.000 description 1
- LJGHYPLBDBRCRZ-UHFFFAOYSA-N 3-(3-aminophenyl)sulfonylaniline Chemical group NC1=CC=CC(S(=O)(=O)C=2C=C(N)C=CC=2)=C1 LJGHYPLBDBRCRZ-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000006275 3-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C([H])C(*)=C1[H] 0.000 description 1
- KZKUUHRXTKUZHT-UHFFFAOYSA-N 3-cyclopropyl-2-(2-oxo-4-propylpyrrolidin-1-yl)propanamide Chemical compound O=C1CC(CCC)CN1C(C(N)=O)CC1CC1 KZKUUHRXTKUZHT-UHFFFAOYSA-N 0.000 description 1
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- AHRLLKUWLXQABV-UHFFFAOYSA-N 4-(3,4-difluorophenyl)-1-(imidazol-1-ylmethyl)pyrrolidin-2-one Chemical compound C1=C(F)C(F)=CC=C1C1CC(=O)N(CN2C=NC=C2)C1 AHRLLKUWLXQABV-UHFFFAOYSA-N 0.000 description 1
- XISMCKKLOWSTSL-UHFFFAOYSA-N 4-(3-azido-2,4,6-trifluorophenyl)-1-(imidazol-1-ylmethyl)pyrrolidin-2-one Chemical compound FC1=C(N=[N+]=[N-])C(F)=CC(F)=C1C1CC(=O)N(CN2C=NC=C2)C1 XISMCKKLOWSTSL-UHFFFAOYSA-N 0.000 description 1
- XVCNDKMWEKVTHG-UHFFFAOYSA-N 4-(4-fluorophenyl)-1-(imidazol-1-ylmethyl)pyrrolidin-2-one Chemical compound C1=CC(F)=CC=C1C1CC(=O)N(CN2C=NC=C2)C1 XVCNDKMWEKVTHG-UHFFFAOYSA-N 0.000 description 1
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
- HEIFVXKWEVAJPS-UHFFFAOYSA-N 4-chloro-1-(imidazol-1-ylmethyl)-3h-indol-2-one Chemical compound O=C1CC=2C(Cl)=CC=CC=2N1CN1C=CN=C1 HEIFVXKWEVAJPS-UHFFFAOYSA-N 0.000 description 1
- 125000006283 4-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Cl)C([H])([H])* 0.000 description 1
- IADRSPWONYSJQZ-UHFFFAOYSA-N 4-fluoro-1-(imidazol-1-ylmethyl)-3h-indol-2-one Chemical compound O=C1CC=2C(F)=CC=CC=2N1CN1C=CN=C1 IADRSPWONYSJQZ-UHFFFAOYSA-N 0.000 description 1
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000006181 4-methyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000000590 4-methylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
- POBLNKARFVBGKB-UHFFFAOYSA-N 4-propyl-1-[(2-propylbenzimidazol-1-yl)methyl]pyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CN1C2=CC=CC=C2N=C1CCC POBLNKARFVBGKB-UHFFFAOYSA-N 0.000 description 1
- WGLPSOPOISZEPO-UHFFFAOYSA-N 4-propyl-1-[(2-propylimidazol-1-yl)methyl]pyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CN1C(CCC)=NC=C1 WGLPSOPOISZEPO-UHFFFAOYSA-N 0.000 description 1
- DNAWBWYYCPAJSG-UHFFFAOYSA-N 4-propyl-1-[[2-(1H-pyrrol-2-yl)benzimidazol-1-yl]methyl]pyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CN1C2=CC=CC=C2N=C1C1=CC=CN1 DNAWBWYYCPAJSG-UHFFFAOYSA-N 0.000 description 1
- KQQGUFXIJMBNAT-UHFFFAOYSA-N 4-propyl-1-[[2-(trifluoromethyl)benzimidazol-1-yl]methyl]pyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CN1C2=CC=CC=C2N=C1C(F)(F)F KQQGUFXIJMBNAT-UHFFFAOYSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- YTFGLCMJIBHPEL-UHFFFAOYSA-N 5-bromo-1-(imidazol-1-ylmethyl)-3h-indol-2-one Chemical compound O=C1CC2=CC(Br)=CC=C2N1CN1C=CN=C1 YTFGLCMJIBHPEL-UHFFFAOYSA-N 0.000 description 1
- JWSQHKDFJAVPTF-UHFFFAOYSA-N 5-chloro-1-[2-(1,4-dioxa-8-azaspiro[4.5]decan-8-yl)-2-oxoethyl]-3h-indol-2-one Chemical compound O=C1CC2=CC(Cl)=CC=C2N1CC(=O)N(CC1)CCC21OCCO2 JWSQHKDFJAVPTF-UHFFFAOYSA-N 0.000 description 1
- HNYNQTVEVFCBPP-UHFFFAOYSA-N 5-chloro-1-[2-(2,5-dihydropyrrol-1-yl)-2-oxoethyl]-3h-indol-2-one Chemical compound O=C1CC2=CC(Cl)=CC=C2N1CC(=O)N1CC=CC1 HNYNQTVEVFCBPP-UHFFFAOYSA-N 0.000 description 1
- OAGQNJWOFCISSA-UHFFFAOYSA-N 5-chloro-1-[2-(3-hydroxypiperidin-1-yl)-2-oxoethyl]-3h-indol-2-one Chemical compound C1C(O)CCCN1C(=O)CN1C2=CC=C(Cl)C=C2CC1=O OAGQNJWOFCISSA-UHFFFAOYSA-N 0.000 description 1
- XDTFFIGOJOJMHY-UHFFFAOYSA-N 5-chloro-1-[2-[4-(2-morpholin-4-ylethyl)piperazin-1-yl]-2-oxoethyl]-3h-indol-2-one Chemical compound O=C1CC2=CC(Cl)=CC=C2N1CC(=O)N(CC1)CCN1CCN1CCOCC1 XDTFFIGOJOJMHY-UHFFFAOYSA-N 0.000 description 1
- GCXZTFDKFBLXBZ-UHFFFAOYSA-N 5-chloro-1-[2-[4-(3-methylphenyl)piperazin-1-yl]-2-oxoethyl]-3h-indol-2-one Chemical compound CC1=CC=CC(N2CCN(CC2)C(=O)CN2C3=CC=C(Cl)C=C3CC2=O)=C1 GCXZTFDKFBLXBZ-UHFFFAOYSA-N 0.000 description 1
- UZBBHOQMFOGAAV-UHFFFAOYSA-N 5-chloro-1-[2-[4-(4-hydroxyphenyl)piperazin-1-yl]-2-oxoethyl]-3h-indol-2-one Chemical compound C1=CC(O)=CC=C1N1CCN(C(=O)CN2C3=CC=C(Cl)C=C3CC2=O)CC1 UZBBHOQMFOGAAV-UHFFFAOYSA-N 0.000 description 1
- BJDMKFNMHOPLFZ-UHFFFAOYSA-N 5-chloro-1-[2-oxo-2-[4-(2-phenylethyl)piperazin-1-yl]ethyl]-3h-indol-2-one Chemical compound O=C1CC2=CC(Cl)=CC=C2N1CC(=O)N(CC1)CCN1CCC1=CC=CC=C1 BJDMKFNMHOPLFZ-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- WPGIUQJYAKHGHL-UHFFFAOYSA-N 7-[(3-bromophenyl)methyl]-3-methyl-8-pentan-3-ylsulfanylpurine-2,6-dione Chemical compound CCC(CC)SC1=NC=2N(C)C(=O)NC(=O)C=2N1CC1=CC=CC(Br)=C1 WPGIUQJYAKHGHL-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 description 1
- 125000000041 C6-C10 aryl group Chemical group 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010012205 Delayed puberty Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 101000584515 Homo sapiens Synaptic vesicle glycoprotein 2B Proteins 0.000 description 1
- 101000584382 Homo sapiens Synaptic vesicle glycoprotein 2C Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229940124041 Luteinizing hormone releasing hormone (LHRH) antagonist Drugs 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical group CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- YNPNZTXNASCQKK-UHFFFAOYSA-N Phenanthrene Natural products C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 1
- 229920005372 Plexiglas® Polymers 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- 101800001295 Putative ATP-dependent helicase Proteins 0.000 description 1
- 101800001006 Putative helicase Proteins 0.000 description 1
- 238000011530 RNeasy Mini Kit Methods 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 102100030700 Synaptic vesicle glycoprotein 2B Human genes 0.000 description 1
- 102100030637 Synaptic vesicle glycoprotein 2C Human genes 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
- MPRPZCNJUPQRGV-PYMCNQPYSA-N [1-[(2s)-1-amino-1-oxobutan-2-yl]-5-oxopyrrolidin-3-yl]methyl 4-methylbenzenesulfonate Chemical compound C1C(=O)N([C@@H](CC)C(N)=O)CC1COS(=O)(=O)C1=CC=C(C)C=C1 MPRPZCNJUPQRGV-PYMCNQPYSA-N 0.000 description 1
- NNDLJCGSVUKDRH-MLWJPKLSSA-N [1-[(2s)-1-amino-1-oxobutan-2-yl]-5-oxopyrrolidin-3-yl]methyl nitrate Chemical compound CC[C@@H](C(N)=O)N1CC(CO[N+]([O-])=O)CC1=O NNDLJCGSVUKDRH-MLWJPKLSSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000001335 aliphatic alkanes Chemical group 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960004909 aminosalicylic acid Drugs 0.000 description 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 125000004658 aryl carbonyl amino group Chemical group 0.000 description 1
- 125000005279 aryl sulfonyloxy group Chemical group 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- ICJCDQBFQWMLJL-UHFFFAOYSA-N azidocyclopropane Chemical group [N-]=[N+]=NC1CC1 ICJCDQBFQWMLJL-UHFFFAOYSA-N 0.000 description 1
- 125000003943 azolyl group Chemical group 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 238000009227 behaviour therapy Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- GCJNEPPUXRIDNB-UHFFFAOYSA-N benzyl n-[3-[(2-oxo-4-propylpyrrolidin-1-yl)methyl]imidazol-4-yl]carbamate Chemical compound O=C1CC(CCC)CN1CN1C(NC(=O)OCC=2C=CC=CC=2)=CN=C1 GCJNEPPUXRIDNB-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 125000004803 chlorobenzyl group Chemical group 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 125000000068 chlorophenyl group Chemical group 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000003930 cognitive ability Effects 0.000 description 1
- 230000006998 cognitive state Effects 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 229940075925 depakote Drugs 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000019621 digestibility Nutrition 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000003890 endocrine cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- DZRDOISWUWDHKK-UHFFFAOYSA-N ethyl 2-(7-butyl-3-methyl-2,6-dioxopurin-8-yl)sulfanylbutanoate Chemical compound CN1C(=O)NC(=O)C2=C1N=C(SC(CC)C(=O)OCC)N2CCCC DZRDOISWUWDHKK-UHFFFAOYSA-N 0.000 description 1
- BCJJLCZTGJBEQG-UHFFFAOYSA-N ethyl 2-[1,3-dimethyl-2,6-dioxo-7-(1-phenylethyl)purin-8-yl]sulfanylbutanoate Chemical compound CCOC(=O)C(CC)SC1=NC=2N(C)C(=O)N(C)C(=O)C=2N1C(C)C1=CC=CC=C1 BCJJLCZTGJBEQG-UHFFFAOYSA-N 0.000 description 1
- VLAFNLAIXYPFJQ-UHFFFAOYSA-N ethyl 2-[3-methyl-2,6-dioxo-7-[(4-sulfamoylphenyl)methyl]purin-8-yl]sulfanylbutanoate Chemical compound CCOC(=O)C(CC)SC1=NC=2N(C)C(=O)NC(=O)C=2N1CC1=CC=C(S(N)(=O)=O)C=C1 VLAFNLAIXYPFJQ-UHFFFAOYSA-N 0.000 description 1
- GPFPPVLLGAANRJ-UHFFFAOYSA-N ethyl 2-[3-methyl-7-(2-methylpropyl)-2,6-dioxopurin-8-yl]sulfanylbutanoate Chemical compound CN1C(=O)NC(=O)C2=C1N=C(SC(CC)C(=O)OCC)N2CC(C)C GPFPPVLLGAANRJ-UHFFFAOYSA-N 0.000 description 1
- YLXSMKPVCZYRQS-UHFFFAOYSA-N ethyl 2-[3-methyl-7-[(3-nitrophenyl)methyl]-2,6-dioxopurin-8-yl]sulfanylbutanoate Chemical compound CCOC(=O)C(CC)SC1=NC=2N(C)C(=O)NC(=O)C=2N1CC1=CC=CC([N+]([O-])=O)=C1 YLXSMKPVCZYRQS-UHFFFAOYSA-N 0.000 description 1
- IHCWIEMGWYWNMT-UHFFFAOYSA-N ethyl 2-[7-(cyclohexylmethyl)-1,3-dimethyl-2,6-dioxopurin-8-yl]sulfanylbutanoate Chemical compound CCOC(=O)C(CC)SC1=NC=2N(C)C(=O)N(C)C(=O)C=2N1CC1CCCCC1 IHCWIEMGWYWNMT-UHFFFAOYSA-N 0.000 description 1
- FDGHTJOWXJSYHI-UHFFFAOYSA-N ethyl 2-[7-[(2-bromophenyl)methyl]-1,3-dimethyl-2,6-dioxopurin-8-yl]sulfanylbutanoate Chemical compound CCOC(=O)C(CC)SC1=NC=2N(C)C(=O)N(C)C(=O)C=2N1CC1=CC=CC=C1Br FDGHTJOWXJSYHI-UHFFFAOYSA-N 0.000 description 1
- JSPOKOWZRMPKST-UHFFFAOYSA-N ethyl 2-[7-[(3-aminophenyl)methyl]-3-methyl-2,6-dioxopurin-8-yl]sulfanylbutanoate Chemical compound CCOC(=O)C(CC)SC1=NC=2N(C)C(=O)NC(=O)C=2N1CC1=CC=CC(N)=C1 JSPOKOWZRMPKST-UHFFFAOYSA-N 0.000 description 1
- XYDKOFORXJHNGG-UHFFFAOYSA-N ethyl 2-[7-[(3-bromophenyl)methyl]-1-(2-methoxyethyl)-3-methyl-2,6-dioxopurin-8-yl]sulfanylbutanoate Chemical compound CCOC(=O)C(CC)SC1=NC=2N(C)C(=O)N(CCOC)C(=O)C=2N1CC1=CC=CC(Br)=C1 XYDKOFORXJHNGG-UHFFFAOYSA-N 0.000 description 1
- JABWCWAILTYCOO-UHFFFAOYSA-N ethyl 2-[7-[(3-bromophenyl)methyl]-3-methyl-2,6-dioxo-1-(2-oxopropyl)purin-8-yl]sulfanylbutanoate Chemical compound CCOC(=O)C(CC)SC1=NC=2N(C)C(=O)N(CC(C)=O)C(=O)C=2N1CC1=CC=CC(Br)=C1 JABWCWAILTYCOO-UHFFFAOYSA-N 0.000 description 1
- JSCNXWSHLUHHGI-UHFFFAOYSA-N ethyl 2-[7-[(3-bromophenyl)methyl]-3-methyl-2,6-dioxo-1-propylpurin-8-yl]sulfanylbutanoate Chemical compound C1=2C(=O)N(CCC)C(=O)N(C)C=2N=C(SC(CC)C(=O)OCC)N1CC1=CC=CC(Br)=C1 JSCNXWSHLUHHGI-UHFFFAOYSA-N 0.000 description 1
- JOPHWRMLCGSCLL-UHFFFAOYSA-N ethyl 2-[8-[(3-bromophenyl)methylsulfanyl]-1,3-dimethyl-2,6-dioxopurin-7-yl]butanoate Chemical compound N=1C=2N(C)C(=O)N(C)C(=O)C=2N(C(CC)C(=O)OCC)C=1SCC1=CC=CC(Br)=C1 JOPHWRMLCGSCLL-UHFFFAOYSA-N 0.000 description 1
- IWEYIBIRQCQRQA-UHFFFAOYSA-N ethyl 2-[[7-[(3-bromophenyl)methyl]-2,6-dioxo-3h-purin-8-yl]sulfanyl]butanoate Chemical compound CCOC(=O)C(CC)SC1=NC=2NC(=O)NC(=O)C=2N1CC1=CC=CC(Br)=C1 IWEYIBIRQCQRQA-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 125000003838 furazanyl group Chemical group 0.000 description 1
- 238000003500 gene array Methods 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 230000005891 glutamate uptake involved in synaptic transmission Effects 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- LHGVFZTZFXWLCP-UHFFFAOYSA-N guaiacol Chemical compound COC1=CC=CC=C1O LHGVFZTZFXWLCP-UHFFFAOYSA-N 0.000 description 1
- 125000000262 haloalkenyl group Chemical group 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000000971 hippocampal effect Effects 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical class C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- QNLOWBMKUIXCOW-UHFFFAOYSA-N indol-2-one Chemical compound C1=CC=CC2=NC(=O)C=C21 QNLOWBMKUIXCOW-UHFFFAOYSA-N 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 230000010365 information processing Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 230000003189 isokinetic effect Effects 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 238000002032 lab-on-a-chip Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000007787 long-term memory Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000013289 male long evans rat Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000008897 memory decline Effects 0.000 description 1
- 230000007334 memory performance Effects 0.000 description 1
- 230000010387 memory retrieval Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Substances OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 1
- LYXNQFYAWOVCST-UHFFFAOYSA-N methyl 1-[(2-oxo-4-propylpyrrolidin-1-yl)methyl]imidazole-2-carboxylate Chemical compound O=C1CC(CCC)CN1CN1C(C(=O)OC)=NC=C1 LYXNQFYAWOVCST-UHFFFAOYSA-N 0.000 description 1
- QGQRAYLWMGXNIZ-UHFFFAOYSA-N methyl 3-[2-(5-chloro-2-oxo-3h-indol-1-yl)acetyl]-1,3-thiazolidine-4-carboxylate Chemical compound COC(=O)C1CSCN1C(=O)CN1C2=CC=C(Cl)C=C2CC1=O QGQRAYLWMGXNIZ-UHFFFAOYSA-N 0.000 description 1
- 125000004458 methylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])[H] 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- DOHCNAGECBUVGH-UHFFFAOYSA-N n'-(4-bromophenyl)-2-(5-chloro-2-oxo-3h-indol-1-yl)acetohydrazide Chemical compound O=C1CC2=CC(Cl)=CC=C2N1CC(=O)NNC1=CC=C(Br)C=C1 DOHCNAGECBUVGH-UHFFFAOYSA-N 0.000 description 1
- FHCHREAHMUFXMM-UHFFFAOYSA-N n-(4-tert-butylphenyl)-2-(5-chloro-2-oxo-3h-indol-1-yl)acetamide Chemical compound C1=CC(C(C)(C)C)=CC=C1NC(=O)CN1C2=CC=C(Cl)C=C2CC1=O FHCHREAHMUFXMM-UHFFFAOYSA-N 0.000 description 1
- LLKJZDONTVVDKL-UHFFFAOYSA-N n-[(2-chloro-6-fluorophenyl)methyl]-2-(5-chloro-2-oxo-3h-indol-1-yl)acetamide Chemical compound FC1=CC=CC(Cl)=C1CNC(=O)CN1C2=CC=C(Cl)C=C2CC1=O LLKJZDONTVVDKL-UHFFFAOYSA-N 0.000 description 1
- IXBXPYHKCYTHGU-UHFFFAOYSA-N n-[[3-[[2-oxo-4-(3,4,5-trifluorophenyl)pyrrolidin-1-yl]methyl]imidazol-4-yl]methyl]acetamide Chemical compound CC(=O)NCC1=CN=CN1CN1C(=O)CC(C=2C=C(F)C(F)=C(F)C=2)C1 IXBXPYHKCYTHGU-UHFFFAOYSA-N 0.000 description 1
- YDGYWBNOIIXKPO-UHFFFAOYSA-N n-[[3-[[2-oxo-4-(3,4,5-trifluorophenyl)pyrrolidin-1-yl]methyl]imidazol-4-yl]methyl]benzamide Chemical compound FC1=C(F)C(F)=CC(C2CC(=O)N(CN3C(=CN=C3)CNC(=O)C=3C=CC=CC=3)C2)=C1 YDGYWBNOIIXKPO-UHFFFAOYSA-N 0.000 description 1
- OCVZZZIJPIYXFN-UHFFFAOYSA-N n-[[3-[[2-oxo-4-(3,4,5-trifluorophenyl)pyrrolidin-1-yl]methyl]imidazol-4-yl]methyl]propanamide Chemical compound CCC(=O)NCC1=CN=CN1CN1C(=O)CC(C=2C=C(F)C(F)=C(F)C=2)C1 OCVZZZIJPIYXFN-UHFFFAOYSA-N 0.000 description 1
- PIEJCUCNBNNZST-UHFFFAOYSA-N n-benzyl-2-(5-chloro-2-oxo-3h-indol-1-yl)-n-methylacetamide Chemical compound O=C1CC2=CC(Cl)=CC=C2N1CC(=O)N(C)CC1=CC=CC=C1 PIEJCUCNBNNZST-UHFFFAOYSA-N 0.000 description 1
- PBIOLHBYAVCIDP-UHFFFAOYSA-N n-butyl-2-(5-chloro-2-oxo-3h-indol-1-yl)acetamide Chemical compound ClC1=CC=C2N(CC(=O)NCCCC)C(=O)CC2=C1 PBIOLHBYAVCIDP-UHFFFAOYSA-N 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- UFWIBTONFRDIAS-UHFFFAOYSA-N naphthalene-acid Natural products C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 238000010855 neuropsychological testing Methods 0.000 description 1
- 230000003957 neurotransmitter release Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- OIPZNTLJVJGRCI-UHFFFAOYSA-M octadecanoyloxyaluminum;dihydrate Chemical compound O.O.CCCCCCCCCCCCCCCCCC(=O)O[Al] OIPZNTLJVJGRCI-UHFFFAOYSA-M 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- CSHWQDPOILHKBI-UHFFFAOYSA-N peryrene Natural products C1=CC(C2=CC=CC=3C2=C2C=CC=3)=C3C2=CC=CC3=C1 CSHWQDPOILHKBI-UHFFFAOYSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 238000002205 phenol-chloroform extraction Methods 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 208000028173 post-traumatic stress disease Diseases 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 1
- 229940080818 propionamide Drugs 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000013535 sea water Substances 0.000 description 1
- 229950000852 seletracetam Drugs 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000006403 short-term memory Effects 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 238000002603 single-photon emission computed tomography Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 230000009154 spontaneous behavior Effects 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 210000002504 synaptic vesicle Anatomy 0.000 description 1
- 102000003137 synaptotagmin Human genes 0.000 description 1
- 108060008004 synaptotagmin Proteins 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- QRTHECVGSAZOPL-UHFFFAOYSA-N thiocyanato cyanate Chemical group N#COSC#N QRTHECVGSAZOPL-UHFFFAOYSA-N 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- XPDWGBQVDMORPB-UHFFFAOYSA-N trifluoromethane acid Natural products FC(F)F XPDWGBQVDMORPB-UHFFFAOYSA-N 0.000 description 1
- 238000009424 underpinning Methods 0.000 description 1
- 229940005605 valeric acid Drugs 0.000 description 1
- NIJJYAXOARWZEE-UHFFFAOYSA-M valproate Chemical compound CCCC(C([O-])=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-M 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 230000003936 working memory Effects 0.000 description 1
- 239000002676 xenobiotic agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10584708P | 2008-10-16 | 2008-10-16 | |
| US61/105,847 | 2008-10-16 | ||
| US15263109P | 2009-02-13 | 2009-02-13 | |
| US61/152,631 | 2009-02-13 | ||
| US17553609P | 2009-05-05 | 2009-05-05 | |
| US61/175,536 | 2009-05-05 | ||
| CN2009801474233A CN102227217A (zh) | 2008-10-16 | 2009-10-16 | 改善认知功能的方法和组合物 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009801474233A Division CN102227217A (zh) | 2008-10-16 | 2009-10-16 | 改善认知功能的方法和组合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107243007A true CN107243007A (zh) | 2017-10-13 |
Family
ID=41403972
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009801474233A Pending CN102227217A (zh) | 2008-10-16 | 2009-10-16 | 改善认知功能的方法和组合物 |
| CN201710440380.4A Pending CN107243007A (zh) | 2008-10-16 | 2009-10-16 | 改善认知功能的方法和组合物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009801474233A Pending CN102227217A (zh) | 2008-10-16 | 2009-10-16 | 改善认知功能的方法和组合物 |
Country Status (11)
| Country | Link |
|---|---|
| US (5) | US20100099735A1 (https=) |
| EP (2) | EP2346500B1 (https=) |
| JP (3) | JP5917148B2 (https=) |
| CN (2) | CN102227217A (https=) |
| AU (1) | AU2009303834B2 (https=) |
| CA (1) | CA2740610C (https=) |
| DK (2) | DK3260118T3 (https=) |
| EA (1) | EA033130B1 (https=) |
| ES (2) | ES2865504T3 (https=) |
| HK (1) | HK1245099A1 (https=) |
| WO (1) | WO2010044878A1 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109892247A (zh) * | 2019-04-19 | 2019-06-18 | 桂林医学院 | 一种猫参与的检测大鼠认知功能的实验装置 |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2865504T3 (es) | 2008-10-16 | 2021-10-15 | Univ Johns Hopkins | Procedimientos y composiciones para la mejora de la función cognitiva |
| EP2672822A4 (en) * | 2011-02-09 | 2014-08-27 | Univ Johns Hopkins | METHOD AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTIONS |
| US20140206667A1 (en) | 2012-11-14 | 2014-07-24 | Michela Gallagher | Methods and compositions for treating schizophrenia |
| EP2968257A4 (en) * | 2013-03-15 | 2016-08-31 | Univ Johns Hopkins | METHOD AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION |
| JP6433482B2 (ja) | 2013-03-15 | 2018-12-05 | エージンバイオ, インコーポレイテッド | 認知機能を改善するための方法および組成物 |
| WO2014144663A1 (en) | 2013-03-15 | 2014-09-18 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
| MA50634A (fr) * | 2015-05-22 | 2021-04-28 | Agenebio Inc | Compositions pharmaceutiques à libération prolongée comportant du lévétiracétam |
| WO2016191288A1 (en) * | 2015-05-22 | 2016-12-01 | Agenebio, Inc. | Extended release pharmaceutical compositions of levetiracetam |
| CN109069480A (zh) | 2015-12-30 | 2018-12-21 | 阿达玛斯医药公司 | 用于治疗与癫痫相关的病症的方法和组合物 |
| WO2017198862A1 (en) * | 2016-05-20 | 2017-11-23 | Institut Pasteur | Methods of treating sepsis with synaptic vesicle 2a and/or 2b binding chemical entities |
| US10370561B2 (en) | 2016-06-28 | 2019-08-06 | Prc-Desoto International, Inc. | Urethane/urea-containing bis(alkenyl) ethers, prepolymers prepared using urethane/urea-containing bis(alkenyl) ethers, and uses thereof |
| US11098222B2 (en) | 2018-07-03 | 2021-08-24 | Prc-Desoto International, Inc. | Sprayable polythioether coatings and sealants |
| CN112569216B (zh) * | 2019-09-30 | 2022-02-15 | 厦门大学 | 戊酸衍生物在治疗唐氏综合征中的应用 |
| CN116075302A (zh) * | 2020-07-10 | 2023-05-05 | 艾吉因生物股份有限公司 | GABAAα5激动剂和SV2A抑制剂的组合以及在认知损害的治疗中的使用方法 |
| JP2024508052A (ja) * | 2021-02-26 | 2024-02-21 | シンデシ セラピューティクス ソシエテ アノニム | 認知障害の治療のための化合物 |
| CN120584115A (zh) | 2022-08-19 | 2025-09-02 | 艾吉因生物股份有限公司 | 苯并氮杂䓬衍生物、组合物和用于治疗认知损害的方法 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070244143A1 (en) * | 2006-03-08 | 2007-10-18 | Braincells, Inc | Modulation of neurogenesis by nootropic agents |
Family Cites Families (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1309692A (en) | 1970-02-13 | 1973-03-14 | Ucb Sa | N-substituted lactams |
| GB1039113A (en) | 1964-08-06 | 1966-08-17 | Ucb Sa | New n-substituted lactams |
| IT1045043B (it) * | 1975-08-13 | 1980-04-21 | Isf Spa | Derivati pirrolidinici |
| IT1075280B (it) * | 1977-02-11 | 1985-04-22 | Isf Spa | Procedimento per la preparazione di derivati pirrolidinici |
| BE864269A (fr) * | 1977-03-03 | 1978-06-16 | Parke Davis & Co | Nouveaux n-(aminoalkyl substitue)-2-oxo-1-pyrrolidine-acetamides et procedes pour les produire |
| EP0005689B1 (fr) * | 1978-05-08 | 1981-03-18 | U C B, S.A. | Nouveaux acides lactame-N-acétiques et leurs amides, leurs procédés de préparation et compositions thérapeutiques |
| US4654370A (en) | 1979-03-12 | 1987-03-31 | Abbott Laboratories | Glyceryl valproates |
| US4372960A (en) * | 1980-12-12 | 1983-02-08 | Warner-Lambert Company | Quaternary derivatives of N-(substituted-aminoalkyl)-2-oxo-1-pyrrolidine-acetamides as cognition activators |
| FR2515179A1 (fr) * | 1981-07-24 | 1983-04-29 | Hoffmann La Roche | Derives de pyrrolidine, leur procede de preparation, les intermediaires pour leur synthese et leur application therapeutique |
| IL67623A (en) * | 1983-01-05 | 1984-09-30 | Teva Pharma | 1'-ethoxycarbonyloxyethyl ester of valproic acid,its preparation and pharmaceutical compositions containing it |
| IL72381A (en) | 1983-07-20 | 1988-03-31 | Sanofi Sa | Pharmaceutical composition based on valproic acid |
| US4558070A (en) | 1983-10-26 | 1985-12-10 | Abbott Laboratories | Acid salts of valproic acid |
| GB8412358D0 (en) * | 1984-05-15 | 1984-06-20 | Ucb Sa | Pharmaceutical composition |
| GB8412357D0 (en) * | 1984-05-15 | 1984-06-20 | Ucb Sa | Pharmaceutical composition |
| US4668687A (en) * | 1984-07-23 | 1987-05-26 | Bristol-Myers Company | Psychogeriatric 1-(2-pyrimidinyl)piperazinyl derivatives of 1-pyrrolidin-2-ones |
| US4913906B1 (en) | 1985-02-28 | 2000-06-06 | Yissum Res Dev Co | Controlled release dosage form of valproic acid |
| JPS6222785A (ja) * | 1985-07-23 | 1987-01-30 | Sanwa Kagaku Kenkyusho:Kk | 新規な2−オキソピロリジン化合物及びその塩、その製法並びにこれらを有効成分とする脳機能障害の予防及び治療剤 |
| IT1190133B (it) * | 1986-06-19 | 1988-02-10 | Chiesi Farma Spa | Derivati di acido valproico e di acido (e)-2-valproenoico,procedimento per la loro preparazione e relative composizioni farmaceutiche |
| DE3709230A1 (de) * | 1987-03-20 | 1988-10-06 | Desitin Arzneimittel Gmbh | Neues calciumsalz der valproinsaeure |
| JPS6422883A (en) * | 1987-07-17 | 1989-01-25 | Sanwa Kagaku Kenkyusho Co | 1-pyrrolidine acetamide derivative, its salt, production thereof and prophylactic and remedial agent for cereral dysfunction containing said derivative and salt as active ingredient |
| ATE68346T1 (de) | 1987-07-22 | 1991-11-15 | Farvalsa Ag | Feuchtigkeitsstabile feste valproinsaeurezubereitung und verfahren zu ihrer herstellung. |
| CA2007732A1 (en) | 1989-01-17 | 1990-07-17 | Gary L. Olson | Cyclohexaneacetamide derivatives |
| FR2643556B1 (fr) | 1989-02-27 | 1993-03-05 | Sanofi Sa | Composition pharmaceutique a liberation prolongee d'acide valproique |
| IT1231477B (it) * | 1989-07-12 | 1991-12-07 | Sigma Tau Ind Farmaceuti | (pirrolidin-2-one-1-il) acetammidi quali attivatori dei processi di apprendimento e della memoria e composizioni farmaceutiche comprendenti tali composti |
| SK279285B6 (sk) * | 1991-05-02 | 1998-09-09 | Daiichi Pharmaceutical Co. | Použitie n-(2,6-dimetylfenyl)-2-(2-oxo-1-pyrolidin |
| US5439930A (en) * | 1992-04-14 | 1995-08-08 | Russian-American Institute For New Drug Development | Biologically active n-acylprolydipeptides having antiamnestic, antihypoxic and anorexigenic effects |
| US5440023A (en) * | 1992-09-18 | 1995-08-08 | Beckman Instruments, Inc. | Method for making valproic acid derivatives |
| GB9319732D0 (en) * | 1993-09-24 | 1993-11-10 | Ucb Sa | Use of (s)-alpha-ethyl-2-oxo-l-pyrrolidineacetamide for the treatment of anxiety |
| US5468733A (en) | 1993-09-30 | 1995-11-21 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| US5516759A (en) | 1994-12-08 | 1996-05-14 | Tap Holdings Inc. | LHRH antagonists having lactam groups at the N-terminus |
| IT1285801B1 (it) | 1996-10-10 | 1998-06-24 | Sigma Tau Ind Farmaceuti | Procedimento migliorato per la preparazione dell'acido valproico |
| US6131106A (en) * | 1998-01-30 | 2000-10-10 | Sun Microsystems Inc | System and method for floating-point computation for numbers in delimited floating point representation |
| US6620802B1 (en) * | 1999-11-23 | 2003-09-16 | Corcept Therapeutics, Inc. | Methods of treating mild cognitive impairment using a glucocorticoid-specific receptor antagonist |
| AR026610A1 (es) | 1999-12-01 | 2003-02-19 | Ucb Sa | Un derivado pirrolidinacetamida solo o en combinacion para tratamiento de desordenes del sistema nervioso central |
| GB0004297D0 (en) | 2000-02-23 | 2000-04-12 | Ucb Sa | 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses |
| EP1356812B1 (en) * | 2000-12-28 | 2009-05-13 | Hamilton Pharmaceuticals, Inc. | Medicines for treatment and prevention of neurogenic pain |
| US6610326B2 (en) * | 2001-02-16 | 2003-08-26 | Andrx Corporation | Divalproex sodium tablets |
| US20040116505A1 (en) * | 2001-02-23 | 2004-06-17 | Gregory Krauss | Treatment of tics, tremors and related disorders |
| WO2002094787A1 (en) | 2001-05-23 | 2002-11-28 | Ucb, S.A. | 2-oxo-piperidinyl- and 2-oxo-azepanyl alkanoic acid derivativ es for the treatment of epilepsy and other neurological disorders |
| JP2005501108A (ja) * | 2001-08-22 | 2005-01-13 | 第一製薬株式会社 | 神経変性治療におけるネフィラセタムの使用 |
| IL161317A0 (en) | 2001-10-16 | 2004-09-27 | Memory Pharm Corp | 4-(4-alkoxy-3-hydroxyphenyl)-2-pyrrolidone derivatives as pde-4 inhibitors for the treatment of neurological syndromes |
| US20040116506A1 (en) * | 2002-06-20 | 2004-06-17 | Krusz John Claude | Use of levetiracetam for treating or preventing acute headaches |
| US7557137B2 (en) * | 2002-08-05 | 2009-07-07 | Bristol-Myers Squibb Company | Gamma-lactams as beta-secretase inhibitors |
| CA2484115C (en) * | 2002-12-03 | 2007-01-30 | Ucb, S.A. | Methods for the identification of agents for the treatment of seizures, neurological diseases, endocrinopathies and hormonal diseases |
| US7090985B2 (en) * | 2002-12-03 | 2006-08-15 | Ucb, S.A. | Methods for the identification of agents for the treatment of seizures, neurological diseases, endocrinopathies and hormonal diseases |
| ITMI20030573A1 (it) * | 2003-03-24 | 2004-09-25 | Nikem Research Srl | Composti ad azione nootropica, loro preparazione, |
| TW200508197A (en) | 2003-03-31 | 2005-03-01 | Ucb Sa | Indolone-acetamide derivatives, processes for preparing them and their uses |
| EA010031B1 (ru) | 2003-12-02 | 2008-06-30 | Юсб, С.А. | Производные имидазола, способы их получения и применения |
| US7618978B2 (en) | 2004-04-22 | 2009-11-17 | Eli Lilly And Company | Amides as BACE inhibitors |
| BRPI0511956A (pt) | 2004-06-11 | 2008-01-22 | Ucb Sa | processo para a preparação dos compostos, e, intermediários de sìntese |
| US20060063707A1 (en) * | 2004-09-17 | 2006-03-23 | Lifelike Biomatic, Inc. | Compositions for enhancing memory and methods therefor |
| CN101111245A (zh) * | 2005-01-27 | 2008-01-23 | 阿雷姆贝克有限公司 | 左乙拉西坦延长释放制剂 |
| US20070298098A1 (en) * | 2005-02-16 | 2007-12-27 | Elan Pharma International Limited | Controlled Release Compositions Comprising Levetiracetam |
| WO2006102750A1 (en) * | 2005-03-30 | 2006-10-05 | Genpharm Inc. | Combined-step process for pharmaceutical compositions |
| US8178533B2 (en) | 2005-06-01 | 2012-05-15 | Ucb Pharma, S.A. | 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses |
| EP1731149A1 (en) * | 2005-06-08 | 2006-12-13 | Ucb S.A. | Use of 2-oxo-1-pyrrolidone derivatives for the treatment of diseases characterized by progressive myoclonic epilepsy |
| GB0517740D0 (en) | 2005-08-31 | 2005-10-12 | Novartis Ag | Organic compounds |
| EP1963325A2 (en) | 2005-12-07 | 2008-09-03 | UCB Pharma, S.A. | Xanthine derivatives, processes for preparing them and their uses |
| US20100216734A1 (en) * | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| JP2009536667A (ja) * | 2006-05-09 | 2009-10-15 | ブレインセルス,インコーポレイティド | 5ht受容体介在性の神経新生 |
| US7858611B2 (en) * | 2006-05-09 | 2010-12-28 | Braincells Inc. | Neurogenesis by modulating angiotensin |
| US20080014264A1 (en) * | 2006-07-13 | 2008-01-17 | Ucb, S.A. | Novel pharmaceutical compositions comprising levetiracetam |
| EP2051696A2 (en) * | 2006-08-18 | 2009-04-29 | Morton Grove Pharmaceuticals, Inc. | Stable liquid levetiracetam compositions and methods |
| AU2007346591A1 (en) | 2007-02-07 | 2008-08-14 | Gosforth Centre (Holdings) Pty Ltd | Treatment of ADHD |
| US20100222326A1 (en) | 2007-04-27 | 2010-09-02 | Ucb Pharma, S.A. | New Heterocyclic Derivatives Useful For The Treatment of CNS Disorders |
| KR20090031333A (ko) | 2007-09-21 | 2009-03-25 | 주식회사 엘지생명과학 | 신규한 베타-세크리타제 저해용 화합물 |
| US20090176740A1 (en) | 2007-11-30 | 2009-07-09 | Phillips Ii Dauglas James | Treatment of neurological conditions by the co-administration of aniracetam and l-alpha glycerylphosphorylcholine |
| PL2273975T3 (pl) * | 2008-03-03 | 2014-09-30 | Ucb Pharma Sa | Roztwory farmaceutyczne, sposoby wytwarzania i zastosowania terapeutyczne |
| JP2010024156A (ja) | 2008-07-16 | 2010-02-04 | Ucb Pharma Sa | レベチラセタムを含む医薬組成物 |
| MX2011001384A (es) | 2008-08-06 | 2011-09-27 | Gosforth Ct Holdings Pty Ltd | Composiciones y metodos para tratar trastornos psiquiatricos. |
| ES2865504T3 (es) | 2008-10-16 | 2021-10-15 | Univ Johns Hopkins | Procedimientos y composiciones para la mejora de la función cognitiva |
| US9125898B2 (en) * | 2008-11-14 | 2015-09-08 | Neurotune Ag | Acetam derivatives for pain relief |
| EP2358360B1 (en) | 2008-11-18 | 2016-09-14 | UCB Biopharma SPRL | Prolonged release formulations comprising an 2-oxo-1-pyrrolidine derivative |
| CN104906085A (zh) | 2009-01-29 | 2015-09-16 | Ucb医药有限公司 | 含有2-氧代-1-吡咯烷衍生物的药物组合物 |
| WO2010089372A1 (en) | 2009-02-09 | 2010-08-12 | Ucb Pharma, S.A. | Pharmaceutical compositions comprising brivaracetam |
| EP2461808A2 (en) | 2009-08-07 | 2012-06-13 | UCB Pharma S.A. | Methods for enhancing the cognitive function |
| WO2016191288A1 (en) * | 2015-05-22 | 2016-12-01 | Agenebio, Inc. | Extended release pharmaceutical compositions of levetiracetam |
-
2009
- 2009-10-16 ES ES17167125T patent/ES2865504T3/es active Active
- 2009-10-16 EA EA201170571A patent/EA033130B1/ru not_active IP Right Cessation
- 2009-10-16 CN CN2009801474233A patent/CN102227217A/zh active Pending
- 2009-10-16 CN CN201710440380.4A patent/CN107243007A/zh active Pending
- 2009-10-16 AU AU2009303834A patent/AU2009303834B2/en active Active
- 2009-10-16 DK DK17167125.8T patent/DK3260118T3/da active
- 2009-10-16 WO PCT/US2009/005647 patent/WO2010044878A1/en not_active Ceased
- 2009-10-16 ES ES09748527.0T patent/ES2637497T3/es active Active
- 2009-10-16 CA CA2740610A patent/CA2740610C/en active Active
- 2009-10-16 JP JP2011532085A patent/JP5917148B2/ja active Active
- 2009-10-16 DK DK09748527.0T patent/DK2346500T3/en active
- 2009-10-16 EP EP09748527.0A patent/EP2346500B1/en active Active
- 2009-10-16 US US12/580,464 patent/US20100099735A1/en not_active Abandoned
- 2009-10-16 EP EP17167125.8A patent/EP3260118B1/en active Active
-
2011
- 2011-11-02 US US13/287,531 patent/US8604075B2/en active Active
-
2014
- 2014-04-25 US US14/261,962 patent/US20150094352A1/en not_active Abandoned
- 2014-06-24 JP JP2014129145A patent/JP2014169339A/ja not_active Withdrawn
-
2016
- 2016-05-25 JP JP2016103917A patent/JP6271641B2/ja active Active
-
2018
- 2018-04-06 HK HK18104537.2A patent/HK1245099A1/zh unknown
-
2021
- 2021-08-17 US US17/404,124 patent/US20220218665A1/en not_active Abandoned
-
2023
- 2023-10-03 US US18/376,127 patent/US20240293363A1/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070244143A1 (en) * | 2006-03-08 | 2007-10-18 | Braincells, Inc | Modulation of neurogenesis by nootropic agents |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109892247A (zh) * | 2019-04-19 | 2019-06-18 | 桂林医学院 | 一种猫参与的检测大鼠认知功能的实验装置 |
| CN109892247B (zh) * | 2019-04-19 | 2023-08-18 | 桂林医学院 | 一种猫参与的检测大鼠认知功能的实验装置 |
Also Published As
| Publication number | Publication date |
|---|---|
| DK3260118T3 (da) | 2021-04-19 |
| CA2740610C (en) | 2020-01-07 |
| EA201170571A1 (ru) | 2011-12-30 |
| JP6271641B2 (ja) | 2018-01-31 |
| US20100099735A1 (en) | 2010-04-22 |
| BRPI0920342A2 (pt) | 2020-06-23 |
| DK2346500T3 (en) | 2017-07-17 |
| JP2014169339A (ja) | 2014-09-18 |
| EA033130B1 (ru) | 2019-08-30 |
| HK1245099A1 (zh) | 2018-08-24 |
| AU2009303834A1 (en) | 2010-04-22 |
| EP2346500A1 (en) | 2011-07-27 |
| US20220218665A1 (en) | 2022-07-14 |
| CN102227217A (zh) | 2011-10-26 |
| EP2346500B1 (en) | 2017-05-17 |
| HK1248543A1 (en) | 2018-10-19 |
| JP2012505883A (ja) | 2012-03-08 |
| JP5917148B2 (ja) | 2016-05-11 |
| US20240293363A1 (en) | 2024-09-05 |
| EP3260118B1 (en) | 2021-03-24 |
| US20150094352A1 (en) | 2015-04-02 |
| ES2637497T3 (es) | 2017-10-13 |
| JP2016147915A (ja) | 2016-08-18 |
| WO2010044878A1 (en) | 2010-04-22 |
| EP3260118A1 (en) | 2017-12-27 |
| CA2740610A1 (en) | 2010-04-22 |
| US20120046336A1 (en) | 2012-02-23 |
| AU2009303834B2 (en) | 2016-08-11 |
| ES2865504T3 (es) | 2021-10-15 |
| US8604075B2 (en) | 2013-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240293363A1 (en) | Methods and compositions for improving cognitive function | |
| US20230277501A1 (en) | Methods and compositions for improving cognitive function | |
| US20230033195A1 (en) | Methods and compositions for improving cognitive function | |
| US20160030391A1 (en) | Methods and compositions for improving cognitive function | |
| HK1248543B (en) | Methods and compositions for improving cognitive function | |
| HK1160005A (en) | Methods and compositions for improving cognitive function | |
| HK1160007B (en) | Methods and compositions for improving cognitive function | |
| HK1160007A (en) | Methods and compositions for improving cognitive function | |
| EA044839B1 (ru) | Способы и композиции для улучшения когнитивной функции | |
| RU2792010C2 (ru) | Способы и композиции для улучшения когнитивных функций | |
| BRPI0920342B1 (pt) | Uso de levetiracetam e de brivracetam, bem como de seus derivados ou análogos ou sais farmaceuticamente aceitáveis dos mesmos | |
| HK1261244A1 (en) | Levetiracetam for improving cognitive function |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1245099 Country of ref document: HK |
|
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20171013 |
|
| RJ01 | Rejection of invention patent application after publication |